<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        27-444-07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2007
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        EMICIPRO 500MG F.C. TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CIPROFLOXACIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        29.7
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="GLOBAL PHARMA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            GLOBAL PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 423]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            MANAYER NAJD TRADING MEDICAL NEEDS CO.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            GLOBAL PHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01MA02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Emicipro contains the active substance ciprofloxacin. Ciprofloxacin is an antibiotic belonging to the fluoroquinolone family. Ciprofloxacin works by killing bacteria that cause infections. It only works with speci_c strains of bacteria.</p><p>Adults</p><p>Emicipro is used in adults to treat the following bacterial infections:</p><p>&bull; respiratory tract infections</p><p>&bull; long lasting or recurring ear or sinus infections</p><p>&bull; urinary tract infections</p><p>&bull; genital tract infections in men and women</p><p>&bull; gastro-intestinal tract infections and intra-abdominal infections</p><p>&bull; skin and soft tissue infections</p><p>&bull; bone and joint infections</p><p>&bull; to prevent infections due to the bacterium Neisseria meningitidis</p><p>&bull; anthrax inhalation exposure</p><p>Ciprofloxacin may be used in the management of patients with low white blood cell counts (neutropenia) who have a fever that is suspected to be due to a bacterial infection.</p><p>If you have a severe infection or one that is caused by more than one type of bacterium, you may be given additional antibiotic treatment in addition to Emicipro.</p><p>Children and adolescents</p><p>Emicipro is used in children and adolescents, under specialist medical supervision, to treat the following bacterial infections:</p><p>&bull; lung and bronchial infections in children and adolescents suffering from cystic fibrosis</p><p>&bull; complicated urinary tract infections, including infections that have reached the kidneys (pyelonephritis)</p><p>&bull; anthrax inhalation exposure</p><p>Emicipro may also be used to treat otherspecific severe infections in children and adolescents when your doctor considered this necessary.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Emicipro:</p><p>&bull; if you are allergic to the active substance, to other quinolone drugs or to any of the other ingredients of this medicine (listed in Section 6)</p><p>&bull; if you are taking tizanidine (see Section 2: Other medicines and Emicipro).</p><p>Warnings and precautions</p><p>Talk to your doctor before taking Emicipro</p><p>&bull; if you have ever had kidney problems because your treatment may need to be adjusted.</p><p>&bull; if you suffer from epilepsy or other neurological conditions.</p><p>&bull; if you have a history of tendon problems during previous treatment with antibiotics such as Emicipro.</p><p>if you are diabetic because you may experience a risk of hypoglycaemia with ciprofloxacin.</p><p>&bull; if you have myasthenia gravis (a type of muscle weakness) because symptoms can be exacerbated.</p><p>&bull; if you have been diagnosed with an enlargement or &ldquo;bulge&rdquo; of a large blood vessel (aortic aneurysm or large vessel peripheral aneurysm).</p><p>&bull; if you have experienced a previous episode of aortic dissection (a tear in the aorta wall).</p><p>&bull; if you have a family history of aortic aneurysm or aortic dissection or other risk factors or predisposing conditions (e.g. connective tissue disorders such as Marfan syndrome, or vascular Ehlers-Danlos syndrome, or vascular disorders such as Takayasu arteritis, giant cell arteritis, Behcet&acute;s disease, high blood pressure, or known atherosclerosis).</p><p>&bull; if you have heart problems. Caution should be taken when using Ciprofloxacin, if you were born with or have family history of prolonged QT interval (seen on ECG, electrical recording of the heart), have salt imbalance in the blood (especially low level of potassium or magnesium in the blood), have a very slow heart rhythm (called &lsquo;bradycardia&rsquo;), have a weak heart (heart failure), have a history of heart attack (myocardial infarction), you are female or elderly or you are taking other medicines that result in abnormal ECG changes (see section 2: Other medicines and Emicipro).</p><p>&bull; if you or a member of your family is known to have a deficiency in glucose-6-phosphate dehydrogenase (G6PD), since you may experience a risk of anaemia with ciprofloxacin.</p><p>For the treatment of some genital tract infections, your doctor can prescribe another antibiotic in addition to &nbsp;ciprofloxacin. If there is no improvement in symptoms after 3 days of treatment, please</p><p>consult your doctor.</p><p>Avoid exposure to strong sunlight, or artificial UV light such as sunbeds.</p><p>&bull; Tell the doctor or laboratory staff that you are taking Emicipro if you have to provide a blood or urine sample.</p><p>&bull; If you suffer from kidney problems, tell the doctor because your dose may need to be adjusted.</p><p>&bull; Emicipro may cause liver damage. If you notice any symptoms such as loss of appetite, jaundice (yellowing of the skin), dark urine, itching, or tenderness of the stomach, stop taking Emicipro and contact your doctor immediately.</p><p>&bull; Emicipro may cause a reduction in the number of white blood cells and your resistance to infection may be decreased. If you experience an infection with symptoms such as fever and serious deterioration of your general condition, or fever with local infection symptoms such as sore throat/pharynx/mouth or urinary problems you should see your doctor immediately. A blood test will be taken to check possible reduction of white blood cells &nbsp;agranulocytosis). It is important to inform your doctor about your medicine.</p><p>Other medicines and Emicipro</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>Do not take Emicipro together with tizanidine, because this may cause side effects such as low blood pressure and sleepiness (see Section 2: Do not take Emicipro).</p><p>The following medicines are known to interact with Emicipro in your body. Taking Emicipro together with these medicines can influence the therapeutic effect of those medicines. It can also increase the probability of experiencing side effects.</p><p>Tell your doctor if you are taking:</p><p>&bull; Vitamin K antagonists (e.g. warfarin, acenocoumarol, phenprocoumon or fluindione) or other oral anti-coagulants (to thin the blood)</p><p>&bull; probenecid (for gout)</p><p>&bull; methotrexate (for certain types of cancer, psoriasis, rheumatoid arthritis)</p><p>&bull; theophylline (for breathing problems)</p><p>&bull; tizanidine (for muscle spasticity in multiple sclerosis)</p><p>&bull; olanzapine (an antipsychotic)</p><p>&bull; clozapine (an antipsychotic)</p><p>&bull; ropinirole (for Parkinson&rsquo;s disease)</p><p>&bull; phenytoin (for epilepsy)</p><p>&bull; metoclopramide (for nausea and vomiting)</p><p>&bull; cyclosporin (for skin conditions, rheumatoid arthritis and in organ transplantation)</p><p>&bull; other medicines that can alter your heart rhythm: medicines that belong to the group of antiarrhythmics (e.g. quinidine, hydroquinidine, disopyramide, amiodarone, sotalol, dofetilide, ibutilide), tricyclic antidepressants, some antimicrobials (that belong to the group of macrolides), some antipsychotics</p><p>&bull; zolpidem (for sleep disorders)</p><p>Emicipro may increase the levels of the following medicines in your blood:</p><p>&bull; pentoxifylline (for circulatory disorders) caffeine</p><p>&bull; duloxetine (for depression, diabetic nerve damage or incontinence)</p><p>&bull; lidocaine (for heart conditions or anaesthetic use)</p><p>&bull; sildenafil (e.g. for erectile dysfunction)</p><p>&bull; agomelatine (for depression)</p><p>Some medicines reduce the effect of Emicipro. Tell your doctor if you take or wish to take:</p><p>&bull; antacids</p><p>&bull; omeprazole</p><p>&bull; mineral supplements</p><p>&bull; sucralfate</p><p>&bull; a polymeric phosphate binder (e.g. sevelamer or lanthanum carbonate)</p><p>&bull; medicines or supplements containing calcium, magnesium, aluminium or iron</p><p>If these preparations are essential, take Emicipro about two hours before or no sooner than four hours</p><p>after them.</p><p>Emicipro with food and drink</p><p>Unless you take Emicipro during meals, do not eat or drink any dairy products (such as milk or yoghurt) or drinks with added calcium when you take the tablets, as they may affect the absorption of the active substance.</p><p>Pregnancy and Breast-feeding</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>It is preferable to avoid the use of Emicipro during pregnancy.</p><p>Do not take Emicipro during breast-feeding because ciprofloxacin is excreted in breast milk and can be harmful for your child.</p><p>Driving and using machines</p><p>Emicipro may make you feel less alert. Some neurological adverse events can occur. Therefore, make sure you know how you react to Emicipro before driving a vehicle or operating machinery. If in doubt, talk to your doctor</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your doctor will explain to you exactly how much Emicipro you will have to take as well as how often and for how long. This will depend on the type of infection you have and how bad it is.</p><p>Tell your doctor if you suffer from kidney problems because your dose may need to be adjusted.</p><p>The treatment usually lasts from 5 to 21 days, but may take longer for severe infections. Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure how many tablets to take and how to take Emicipro.</p><p>a. Swallow the tablets with plenty of fluid. Do not chew the tablets because they do not taste nice.</p><p>b. Do try to take the tablets at around the same time every day.</p><p>c. You can take the tablets at mealtimes or between meals. Any calcium you take as part of a meal will not seriously affect uptake. However, do not take Emicipro tablets with dairy products such as milk or yoghurt or with fortified fruit juices (e.g. calcium-fortified orange juice).</p><p>Remember to drink plenty of fluids while you are taking this medicine.</p><p>If you take more Emicipro than you should If you take more than the prescribed dose, get medical help immediately. If possible, take your tablets or the box with you to show the doctor.</p><p>If you forget to take Emicipro</p><p>Take the normal dose as soon as possible and then continue as prescribed. However, if it is almost time for your next dose, do not take the missed dose and continue as usual. Do not take a double dose to make up for a forgotten dose. Be sure to complete your course of treatment.</p><p>If you stop taking Emicipro</p><p>It is important that you finish the course of treatment even if you begin to feel better after a few days. If you stop taking this medicine too soon, your infection may not be completely cured and the symptoms of the infection may return or get worse. You might also develop resistance to the antibiotic.</p><p>If you have any further questions about the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>The following section contains the most serious side effects that you can recognize yourself:</p><p>Stop taking Emicipro and contact your doctor immediately in order to consider another antibiotic treatment if you notice any of the following serious side effects:</p><p>Rare (may affect up to 1 in 1,000 people)</p><p>- Seizure (see Section 2: Warnings and precautions)</p><p>Very rare (may affect up to 1 in 10,000 people</p><p>- Severe, sudden allergic reaction with symptoms such as tightness in the chest, feeling dizzy, sick or faint, or experience dizziness when standing up (anaphylactic reaction/shock) (see Section 2:</p><p>Warnings and precautions)</p><p>- Muscle weakness, inflammation of the tendons which could lead to rupture of the tendon, particularly affecting the large tendon at the back of the ankle (Achilles tendon) (see Section 2: Warnings and precautions)</p><p>- A serious life-threatening skin rash, usually in the form of blisters or ulcers in the mouth, throat, nose, eyes and other mucous membranes such as genitals which may progress to widespread blistering or peeling of the skin (Stevens-Johnson syndrome, toxic epidermal necrolysis).</p><p>Not known (frequency cannot be estimated from the available data)</p><p>- Unusual feelings of pain, burning tingling, numbness or muscle weakness in the extremities (neuropathy) (see Section 2: Warnings and precautions)</p><p>- A drug reaction that causes rash, fever, inflammation of internal organs, hematologic abnormalities and systemic illness (DRESS Drug Reaction with Eosinophilia and Systemic Symptoms, AGEP Acute Generalised Exanthematous Pustulosis).</p><p>Other side effects which have been observed during treatment with ciprofloxacin are listed below by how likely they are:</p><p>Common: may affect up to 1 in 10 people</p><p>- nausea, diarrhoea</p><p>- joint pain and joint inflammation in children</p><p>Uncommon: may affect up to 1 in 100 people</p><p>- joint pain in adults</p><p>- fungal superinfections</p><p>- a high concentration of eosinophils, a type of white blood cell</p><p>- decreased appetite</p><p>- hyperactivity or agitation</p><p>- headache, dizziness, sleeping problems, or taste disorders</p><p>- vomiting, abdominal pain, digestive problems such as stomach upset (indigestion/heartburn), or wind</p><p>- increased amounts of certain substances in the blood (transaminases and/or bilirubin)</p><p>- rash, itching, or hives</p><p>- poor kidney function</p><p>- pains in your muscles and bones, feeling unwell (asthenia), or fever</p><p>- increase in blood alkaline phosphatase (a certain substance in the blood)</p><p>Rare: may affect up to 1 in 1,000 people</p><p>- muscle pain, inflammation of the joints, increased muscle tone, and cramping</p><p>- inflammation of the bowel (colitis) linked to antibiotic use (can be fatal in very rare cases) (see Section 2: Warnings and precautions)</p><p>- changes to the blood count (leukopenia, leukocytosis, neutropenia, anaemia), increased or decreased amounts of a blood clotting factor (thrombocytes)</p><p>- allergic reaction, swelling (oedema), or rapid swelling of the skin and mucous membranes (angio-oedema) (see Section 2: Warnings and precautions)</p><p>- increased blood sugar (hyperglycaemia)</p><p>- decreased blood sugar (hypoglycaemia) (see Section 2: Warnings and precautions)</p><p>- confusion, disorientation, anxiety reactions, strange dreams, depression (potentially leading to thoughts of suicide, suicide attempts, or completed suicide) (see Section 2: Warnings and precautions), or hallucinations</p><p>- pins and needles, unusual sensitivity to stimuli of the senses, decreased skin sensitivity, tremors, or giddiness</p><p>- eyesight problems including double vision (see Section 2: Warnings and precautions)</p><p>- tinnitus, loss of hearing, impaired hearing</p><p>- rapid heartbeat (tachycardia)</p><p>- expansion of blood vessels (vasodilation), low blood pressure, or fainting</p><p>- shortness of breath, including asthmatic symptoms</p><p>- liver disorders, jaundice (cholestatic icterus), or hepatitis</p><p>- sensitivity to light (see Section 2: Warnings and precautions)</p><p>- kidney failure, blood or crystals in the urine , urinary tract inflammation</p><p>- fluid retention or excessive sweating</p><p>- increased levels of the enzyme amylase</p><p>Very rare: may affect up to 1 in 10,000 people</p><p>- a special type of reduced red blood cell count (haemolytic anaemia); a dangerous drop in a type of white blood cells (agranulocytosis) (see Section 2: Warnings and precautions); a drop in the number of red and white blood cells and platelets (pancytopenia), which may be fatal; and bone marrow depression, which may also be fatal</p><p>- allergic reaction called serum sickness-like reaction (see Section 2: Warnings and precautions)</p><p>- mental disturbances (psychotic reactions potentially leading to thoughts of suicide, suicide</p><p>attempts, or completed suicide) (see Section 2: Warnings and precautions)</p><p>- migraine, disturbed coordination, unsteady walk (gait disturbance), disorder of sense of smell (olfactory disorders), pressure on the brain (intracranial pressure and pseudotumor cerebri) visual colour distortions</p><p>- inflammation of the wall of the blood vessels (vasculitis)</p><p>- pancreatitis</p><p>- death of liver cells (liver necrosis) very rarely leading to life-threatening liver failure (see Section 2:Warnings and precautions)</p><p>- small, pin-point bleeding under the skin (petechiae); various skin eruptions or rashes</p><p>- worsening of the symptoms of myasthenia gravis (see Section 2: Warnings and precautions)</p><p>Not known: frequency cannot be estimated from the available data</p><p>- syndrome associated with impaired water excretion and low levels of sodium (SIADH)</p><p>- feeling highly excited (mania) or feeling great optimism and overactivity (hypomania)</p><p>- abnormal fast heart rhythm, life-threatening irregular heart rhythm, alteration of the heart rhythm</p><p>(called &lsquo;prolongation of QT interval&rsquo;, seen on ECG, electrical activity of the heart)</p><p>- influence on blood clotting (in patients treated with Vitamin K antagonists)</p><p>If you get any side effects, talk to</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep all medicines out of the sight and reach of children. Do not store above 30&deg; C.<br />Store in a dry place. Protect from light. Do not use Emicipro after the expiry date which is stated after&nbsp;&lsquo;EXP&rsquo; on the blister and carton. Medicines should not be disposed of via wastewater or household waste.<br />Ask your pharmacist how to dispose of medicines no longer required. These measures will help to&nbsp;protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is ciprofloxacin. Each film-coated tablet contains 582 mg of ciprofloxacin&nbsp;hydrochloride equivalent to 500 mg of ciprofloxacin. The other ingredients are:<br />Tablet core: Maize Starch, Microcrystalline cellulose, Sodium Lauryl Sulfate, Magnesium Stearate,&nbsp;Purified Talc, Colloidal Anhydrous Silica, Sodium Starch Glycollate, Crospovidone,<br />Film-coat: Hypromellose, Polyethylene glycol, Titanium Dioxide, Simethicone emulsion.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                White to off-white oval film coated tablets with GP27 embossed on one side and plain on the other side.
Pack size of 10 film-coated tablets ( 10’s Blister X 1 ).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Globalpharma Co. LLC, P.O. Box 72168, Dubai, UAE.<br />Tel: +97148090900, Email: info@globalpharma.ae</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in April 2019 ( RLD 01/19)
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">إميسبرو يحتوي على المادة الفعالة سيبروفلوكساسين ، يعتبر سيبروفلوكساسين&nbsp; من المضادات الحيوية التي تنتمي إلى فئة الفلوروكينولون. يقوم سيبروفلوكساسين بالقضاء على البكتيريا التي تسبب العدوى، ولا يُؤثر إلا على سلالات بكتيريا محددة.</p><p dir="RTL">البالغون</p><p dir="RTL">يتم استخدام إميسيبرو في البالغين؛ لعلاج العدوى البكتيرية التالية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجهاز التنفسي.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; العدوى المتكررة في الجيوب الأنفية أو الأذن أو التي تستمر لفترات طويلة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجهاز البولي.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; عدوى الجهاز التناسلي في الرجال والنساء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجهاز الهضمي والعدوى داخل البطن.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull;&nbsp;&nbsp;&nbsp; عدوى الجلد والأنسجة الرخوة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى العظام والمفاصل.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; للوقاية من العدوى الناتجة عن بكتيريا النَّيسَرِيَّة السِّحائِيَّة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعرض لاستنشاق بكتيريا الجمرة الخبيثة.</p><p dir="RTL">يمكن إستخدام سيبروفلوكساسين في علاج المرضى الذين يعانون من قلة عدد كريات الدم البيضاء (قلَّةُ العَدِلَات) والمصابين بحُمى يُشتبه أن تكون بسبب تعرضهم لعدوى بكتيرية.</p><p dir="RTL">إذا كنت تعاني من عدوى شديدة أو عدوى ناتجة عن أكثر من نوع واحد من أنواع البكتيريا، فربما يتم إعطاؤك علاجًا إضافيًّا بمضادات حيوية أخرى بالإضافة لإميسبرو.</p><p dir="RTL">الأطفال والمراهقون</p><p dir="RTL">يتم استخدام إميسبرو في الأطفال والمراهقين، تحت إشراف طبي متخصص، لعلاج العدوى البكتيرية التالية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الرئة والشعب الهوائية في الأطفال والمراهقين الذين يعانون من تليف كيسي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجهاز البولي المصحوبة بمضاعفات، بما في ذلك العدوى التي امتدت إلى الكليتين (التهاب الحويضة والكلية).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعرض لاستنشاق بكتيريا الجمرة الخبيثة.</p><p dir="RTL">إذا وجد طبيبك أن ذلك ضروريٌّ، فيمكن أيضًا استخدام إميسبرو لعلاج حالات أخرى لعدوى شديدة معينة في الأطفال والمراهقين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تتناول إميسبروفي الحالات الآتية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الحساسية (حساسية مفرطة) تجاه المادة الفعالة أو تجاه عقاقير كينولون أخرى أو أيٍّ من مكونات هذا الدواء الأخرى (انظر قسم 6).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول عقار تيزانيدين (انظر قسم 2 &quot;تناول أدوية أخرى مع إميسبرو&quot;).</p><p dir="RTL">تحذيرات وإحتياطات</p><p dir="RTL">تحدث مع طبيبك قبل أن تتناول إميسبرو</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد عانيت مسبقًا من مشاكل في الكلى حيث قد تحتاج إلى تعديل العلاج الذي تتناوله.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من صرع أو حالات عصبية أخرى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ مرضي من الإصابة بمشاكل بالأوتار خلال علاج مسبق بمضادات حيوية مثل إميسبرو.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابا بداء السكري لأنك قد تواجه مخاطر نقص سكر الدم مع سيبروفلوكساسين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض الوهن العضلي الوبيل (نوع من أنواع ضعف العضلات) لأن الأعراض يمكن أن تتفاقم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; إذا تم تشخيص حالتك بتَضخُّم أو &quot;انتفاخ&quot; في أحد الأوعية الدَّموية الكبيرة (تمدد الأوعية الدَّموية بالشريان الأبهر أو تمدد الأوعية الدَّموية الكبيرة الطرفية).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; إذا عانيت سابقًا من نوبة تسلخ الشريان الأبهر (تمزق بجدار الشريان الأبهر).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ مرضي عائلي من الإصابة بتمدد الأوعية الدَّموية بالشريان الأبهر أو تسلخ الشريان الأبهر أو إذا كنت تعاني من عوامل خطورة أخرى أو حالات مهيئة (على سبيل المثال: اضطرابات الأنسجة الضامة مثل متلازمة مارفان أو متلازمة إهلرز-دانلوس التي تصيب الأوعية الدَّموية أو اضطرابات الأوعية الدَّموية مثل الْتِهاب الشَّرايينِ بحَسَبِ تكاياسو، التهاب الشريان ذي الخلايا العملاقة، مرض بهجت، ارتفاع ضغط الدَّم أو تصلب الشرايين المعروف).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل في القلب. يجب توخي الحذر عند استخدام سيبروفلوكساسين، إذا كنت تعاني من إطالة فترة QT منذ الولادة (تتم ملاحظته في رسم القلب ECG)، أو لدى عائلتك تاريخ مرضي للإصابة بها أو تعاني من عدم توازن مستويات الأملاح في الدم (خاصة انخفاض مستويات البوتاسيوم أو الماغنسيوم في الدم)، أو تعاني من بطء شديد في النظم القلبي (بطء القلب)، أو تعاني من ضعف القلب (هبوط / فشل القلب)، أو لديك تاريخ مرضي من الإصابة بنوبات القلب (احتشاء عضلة القلب)، أو كنتِ أنثى أو من المسنين أو كنت تتناول أدوية أخرى تؤدي إلى تغييرات غير طبيعية في رسم القلب (انظر قسم 2: &quot;تناول أدوية أخرى مع إميسبرو&quot;).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني أنت أو أحد أفراد أسرتك من نقص إنزيم نازعة هيدروجين الجلوكوز-6-فوسفات (G6PD)، حيث قد تعاني من مخاطر الإصابة بفقر الدم نتيجة تناول سيبروفلوكساسين.</p><p dir="RTL">لعلاج بعض أنواع عدوى الجهاز التناسلي، يمكن أن يصف طبيبك مضادًّا حيويًّا آخرَ بالإضافة إلى سيبروفلوكساسين. يُرجى استشارة طبيبك إذا لم يحدث تحسن في الأعراض بعد مرور 3 أيام من العلاج.</p><p dir="RTL">أثناء تناول إميسبرو</p><p dir="RTL">أخبر طبيبك على الفور إذا حدث أي مما يلي أثناء تناول إميسبرو، وسوف يقرر طبيبك ما إذا كان ينبغي إيقاف العلاج بإميسبرو أم لا.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل حساسية شديد ومفاجئ (تفاعل تأقي/ صدمة تأقية، وذمة وعائية). حتى مع تناول الجرعة الأولى ، قد يكون هناك احتمال ضئيل أن تعاني من تفاعل حساسية شديد مع ظهور الأعراض التالية: ضيق في الصدر، أو شعور بدوخة، أو إعياء، أو إغماء أو إصابتك بدوخة عند النهوض. إذا حدث ذلك، فتوقف عن تناول إميسبرو واتصل بطبيبك على الفور.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يحدث في بعض الأحيان ألم وتورم في المفاصل والأوتار، خاصة إذا كنت كبيرًا في السن، ويتم علاجك أيضًا بالكورتيكوستيرويدات. قد يحدث التهاب في الأوتار أو تمزقها حتى أثناء أول 48 ساعة من العلاج، أو قد يستمر ذلك إلى عدة شهور بعد إيقاف العلاج بإميسبرو. عند ظهور أولى علامات الألم أو الالتهاب توقف عن تناول إميسبرو وأرح المنطقة المؤلمة. تجنب ممارسة أي تمارين غير ضرورية، حيث قد يزيد ذلك من احتمال حدوث تمزق في الأوتار.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا شعرت بألم مفاجئ وشديد ببطنك أو صدرك أو ظهرك، اذهب إلى غرفة الطوارئ على الفور.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من صرع أو حالات عصبية أخرى مثل الإقفار الدماغي أو السكتة الدماغية، فقد تعاني من آثار جانبية مرتبطة بالجهاز العصبي المركزي. إذا حدث ذلك، فتوقف عن تناول إميسبرو، واتصل بطبيبك على الفور.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تعاني من تفاعلات نفسية عند تناولك إميسبرو للمرة الأولى. إذا كنت تعاني من اكتئاب أو ذهان؛ فقد تسوء الأعراض أثناء العلاج بإميسبرو. في حالات نادرة، يحدث تدهور للاكتئاب أو الذهان ليصبح أفكار انتحارية أو محاولات انتحار أو انتحار بالفعل. إذا حدث ذلك، فتوقف عن تناول إميسبروواتصل بطبيبك على الفور.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تعاني من أعراض اعتلال الأعصاب مثل: ألم، حرقة، وخز، تنميل و/أو ضعف. إذا حدث ذلك، فتوقف عن تناول إميسبرو واتصل بطبيبك على الفور.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تسبب المضادات الحيوية التي تنتمي إلى فئة الكينولون اضطرابات في نسبة السكر في الدم ، ويشمل ذلك كلا من انخفاض نسبة السكر في الدم لأقل من المستويات الطبيعية (نقص سكر الدم) و زيادة نسبة السكر في الدم لأعلى من المستويات الطبيعية (ارتفاع سكرالدم) (انظر القسم 4. التأثيرات الجانبية المحتملة).</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp; تحدث الاضطرابات في نسبة السكر في الدم عادة لدى مرضى السكري المسنين ، الذين يتلقون علاجًا مصاحبًا عن طريق الفم للأدوية المضادة لمرض السكر التي تخفض نسبة السكر في الدم (مثل جليبنكلاميد) أو مع الأنسولين. تم الإبلاغ عن فقدان الوعي بسبب الانخفاض الحاد في نسبة السكر في الدم (غيبوبة سكر الدم). إذا كنت تعاني من داء السكري ، فيجب العناية&nbsp; بمراقبة نسبة السكر في الدم لديك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تعاني من إسهال أثناء تناولك مضادات حيوية، بما في ذلك إميسبرو، أو حتى بعد عدة أسابيع من توقفك عن تناولها. إذا أصبح هذا الإسهال شديدًا أو مستمرًّا أو لاحظت أن البراز يحتوي على دم أو مخاط، فتوقف عن تناول إميسبروعلى الفور، حيث قد يكون ذلك أمرًا مهددًا للحياة. لا تتناول أية أدوية لإيقاف حركة الأمعاء أو إبطائها، واتصل بطبيبك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا حدث ضعف في الإبصار أو بدا أن عينيك قد تأثرت ، استشر طبيب&nbsp; متخصص بطب العيون على الفور.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يصبح جلدك أكثر حساسية لأشعة الشمس أو الأشعة فوق البنفسجية عند تناول إميسبرو. تجنب التعرض لأشعة الشمس القوية، أو الأشعة فوق البنفسجية الصناعية مثل الكبائن الشمسية (آسرة تسمير البشرة).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا توجب عليك تقديم عينة دم أو بول فأخبر الطبيب أو فريق العمل بالمختبر بأنك تتناول إميسبرو.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل بالكلى، فأخبر الطبيب حيث قد يستلزم الأمر تعديل الجرعة المحددة لك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يسبب إميسبرو تلف الكبد. إذا لاحظت أية أعراض مثل: فقدان الشهية، أو اليرقان (اصفرار البشرة)، أو أصبح البول داكنًا، أو لديك حكة، أو ألم في المعدة، فتوقف عن تناول إميسبرو، واتصل بطبيبك على الفور.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يُسبب إميسبروانخفاضًا في عدد كريات الدم البيضاء، وقد تنخفض مقاومتك للعدوى. إذا عانيت من عدوى مصحوبة بأعراض مثل: الحمى، وتدهور الحالة العامة بشكل خطير، أو حمى مصحوبة بأعراض عدوى موضعية مثل احتقان الحلق/ البلعوم/ الفم أو مشاكل في الجهاز البولي يجب أن تستشير طبيبك على الفور. قد يتم إجراء اختبار دم للتحقق من الانخفاض المحتمل في عدد كريات الدم البيضاء (ندْرَةُ المُحَبَّبات). من المهم إبلاغ طبيبك عن تناولك لهذا الدواء.</p><p dir="RTL">تناول أدوية أخرى مع إميسبرو</p><p dir="RTL">برجاء إبلاغ الطبيب أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أية أدوية أخرى، بما فيها الأدوية التي حصلت عليها دون وصفة طبية.</p><p dir="RTL">لا تتناول إميسبرومع عقار تيزانيدين، حيث قد يُسبب ذلك آثارًا جانبية مثل انخفاض ضغط الدم والنعاس (انظر قسم 2: &quot;لا تتناول إميسبرو&quot;).</p><p dir="RTL">تُعرف الأدوية التالية بتداخلها مع إميسبرو في الجسم. من الممكن أن يُؤثر التناول المتزامن لإميسبرومع هذه الأدوية على التَّأثير العلاجي لهذه الأدوية. كذلك قد يزيد من احتمالية حدوث تأثيرات جانبية.</p><p dir="RTL">أخبر طبيبك إذا كنت تتناول:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مناهضات فيتامين ك (مثل:عقار وارفارين ، أَسينوكومارول ، فينبروكومون ، فلوينديون) أو مضادات تجلط أخرى تؤخذ عن طريق الفم (لزيادة سيولة الدم).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عقار بروبينيسيد (الذي يُستخدم لعلاج النقرس).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عقار ميثوتريكسات (الذي يُستخدم لعلاج بعض أنواع السرطان والصدفية والتهاب المفاصل الروماتويدي).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عقار ثيوفيلين (الذي يُستخدم لعلاج مشاكل التنفس).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عقار تيزانيدين (الذي يُستخدم لعلاج فرط التوتر العضلي المصاحب لمرض التصلب المتعدد).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عقار أولانزابين (مضاد للذهان).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عقار كلوزابين (مضاد للذهان).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عقار روبينيرول (الذي يُستخدم لعلاج مرض باركنسون).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عقار فينيتوين (الذي يُستخدم لعلاج الصرع).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عقار ميتوكلوبراميد (الذي يُستخدم لعلاج الغثيان والقيء).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عقار سيكلوسبورين (الذي يُستخدم لعلاج حالات الجلد والتهاب المفاصل الروماتويدي وفي زراعة الأعضاء).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية أخرى يمكنها تغيير النظم القلبي: أدوية تنتمي إلى فئة مضادات اضطرابات النظم القلبي (مثل عقار كينيدين، وعقار هيدروكيندين، وعقار ديسوبيراميد، وعقار أميودارون، وعقار سوتالول، وعقار دوفيتيليد، وعقار إيبوتيليد)، ومضادات الاكتئاب ثلاثية الحلقات، وبعض مضادات الميكروبات (التي تنتمي إلى مجموعة الماكروليدات)، وبعض مضادات الذهان.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عقار زولبيديم (لاضطرابات النوم)</p><p dir="RTL">قد يزيد إميسبرو من مستويات الأدوية التالية في الدم:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عقار بنتوكسيفيلين (الذي يُستخدم لعلاج اضطرابات الدورة الدموية).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مادة الكافيين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عقار ديلوكسيتين (الذي يُستخدم لعلاج الاكتئاب أو التلف العصبي الناتج عن داء السكري أو سلس البول).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عقار ليدوكايين (الذي يستخدم لعلاج حالات القلب أو للتخدير).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عقار سيلدينافيل (الذي يستخدم على سبيل المثال لعلاج خلل الانتصاب ).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أغوميلاتين (للاكتئاب )</p><p dir="RTL">تقلل بعض الأدوية من تأثير إميسبرو. أخبر طبيبك إذا كنت تتناول أو ترغب في تناول:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات حموضة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عقار أوميبرازول.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مكملات غذائية تحتوي على معادن.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عقار سوكرالفات.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البوليمرات الرابطة للفوسفات (مثل عقار سيفيلامير أو كربونات اللانثالوم).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية أو مكملات غذائية تحتوي على كالسيوم أو ماغنسيوم أو ألمونيوم أو حديد.</p><p dir="RTL">إذا كان تناول هذه المستحضرات ضروريًّا، فتناول إميسبرو قبل تناولها بحوالي ساعتين أو بعد تناولها بفترة لا تقل عن أربع ساعات.</p><p dir="RTL">تناول إميسبرومع الأغذية والمشروبات</p><p dir="RTL">ما لم تكن تتناول إميسبروأثناء الوجبات، فلا تأكل أو تشرب أي من منتجات الألبان (مثل اللبن أو الزبادي) أو مشروبات بها كالسيوم مضاف عند تناول الأقراص؛ لأنها قد تُؤثر على امتصاص المادة الفعالة.</p><p dir="RTL">الحمل والرضاعة الطبيعية</p><p dir="RTL">إذا كنتِ حاملًا أو مرضع ، أو تعتقدين أنكِ حامل أو تخططين لذلك ، فاستشيري طبيبك أو الصيدلي الخاص بك قبل تناوُل هذا الدَّواء. يفضل تجنب استخدام إميسبرو خلال الحمل.</p><p dir="RTL">لا تتناولي إميسبرو خلال الرضاعة الطبيعية حيث قد يمر سيبروفلوكساسين إلى لبن الأم وقد يضر طفلك.</p><p dir="RTL">القيادة واستخدام الآلات</p><p dir="RTL">قد يقلل إميسبرومن يقظتك. قد تحدث بعض التأثيرات الجانبية العصبية ؛ لذا، تأكد من كيفية تأثير إميسبروعليك قبل قيادة مركبة أو تشغيل آلة. تحدث إلى طبيبك إذا كنت غير متأكد.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيشرح لك طبيبك بالضبط الكمية التي سيجب عليك تناولها من إميسبرو بالإضافة إلى عدد المرات ومدة العلاج. سيتوقف ذلك على نوع العدوى التي تعاني منها ومدى سؤها.</p><p dir="RTL">إذا كنت تعاني من مشاكل بالكلى، فأخبر طبيبك حيث قد يستلزم الأمر تعديل الجرعة المحددة لك.</p><p dir="RTL">عادة ما يستغرق العلاج فترة تتراوح بين 5 أيام و21 يومًا، ولكن قد يستغرق فترة أطول من ذلك في حالة العدوى الشديدة. تناول الأقراص كما أخبرك طبيبك بالضبط. استشر الطبيب أو الصيدلي الخاص بك إذا لم تكن متأكدًا من عدد الأقراص التي يجب عليك تناولها وكيفية تناول إميسبرو.</p><p dir="RTL">ا.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابتلع الأقراص مع كمية كبيرة من السوائل. لا تمضغ الأقراص؛ لأن مذاقها ليس جيدًا.</p><p dir="RTL">ب.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حاول أن تتناول الأقراص في نفس الوقت تقريبًا من كل يوم.</p><p dir="RTL">ت.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكنك تناول الأقراص أثناء الوجبات أو بين الوجبات. لن يُؤثر أي كالسيوم تتناوله كجزء من الوجبة بشكل خطير على الامتصاص. مع ذلك، لا تتناول أقراص إميسبرو مع منتجات الألبان مثل اللبن أو الزبادي أو مع عصائر الفاكهة المعززة (مثل عصير البرتقال المعزز بالكالسيوم).</p><p dir="RTL">تذكر أن تشرب كمية كبيرة من السوائل أثناء تناول إميسبرو.</p><p dir="RTL">إذا تناولت كمية من إميسبروأكثر مما يجب:</p><p dir="RTL">إذا تناولت أكثر من الجرعة الموصوفة، فاطلب المساعدة الطبية على الفور. إن أمكن، خذ معك الأقراص أو العبوة؛ لتريها</p><p dir="RTL">للطبيب.</p><p dir="RTL">إذا نسيت تناول إميسبرو</p><p dir="RTL">تناول الجرعة المعتادة بأسرع ما يمكن، ثم استكمل تناول جرعاتك بالطريقة الموصوفة لك. مع ذلك، إذا أوشك وقت تناول</p><p dir="RTL">جرعتك التالية، لا تتناول الجرعة التي نسيتها وتناول الجرعات كالمعتاد. لا تتناول جرعة مضاعفة لتعويض جرعة نسيتها.</p><p dir="RTL">احرص على إكمال دورة علاجك.</p><p dir="RTL">إذا توقفت عن تناول إميسبرو</p><p dir="RTL">من المهم أن تنهي دورة العلاج حتى إذا بدأت تشعر بتحسن بعد أيام قليلة. حيث إنه إذا توقفت عن تناول هذا الدواء في وقت مبكر</p><p dir="RTL">عما هو مفترض فقد لا تكون العدوى قد شفيت تمامًا، وقد تعود أعراض العدوى أو تسوء. كما قد تتطور لديك مقاومة؛ لتأثير</p><p dir="RTL">المضاد الحيوي.</p><p dir="RTL">إذا كان لديك أية استفسارات حول استخدام هذا المنتج، فاسأل الطبيب أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية ، يمكن أن يسبب هذا الدواء تأثيرات جانبية ، لكنها لا تحدث للجميع.</p><p dir="RTL">يحتوي القسم التالي على التأثيرات الجانبية الأكثر خطورة التي يمكن أن تدركها بنفسك:</p><p dir="RTL">توقف عن تناول إميسبرو واتصل بطبيبك على الفور من أجل النظر في العلاج بالمضادات الحيوية آخر إذا لاحظت أي من التأثيرات الجانبية التالية:</p><p dir="RTL">نادرة (قد تؤثر فیما یصل إلى شخص من بین كل 1000 شخص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات صرع (انظر القسم 2: تحذيرات واحتياطات)</p><p dir="RTL">نادرة جدا (قد تؤثر فیما یصل إلى شخص من بین كل 10000 شخص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية شديدة مفاجئة مع أعراض مثل ضيق في الصدر، الشعور بالدوار ، التوعك أو الإغماء ، أو التعرض لدوخة عند الوقوف (تفاعل تأقي /&nbsp; صدمة) (انظر القسم 2: تحذيرات واحتياطات)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف عضلي أو التهاب الأوتارالتي يمكن أن تؤدي الى تمزق الأوتار، خاصة الأوتار الكبيرة في الجزء الخلفي من الكاحل (وتر العرقوب) (انظر قسم 2:&quot; تحذيرات وإحتياطات&quot;)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي بليغ مهدد للحياة ، عادة على شكل بثور أو قروح في الفم والحلق والأنف والعينين وغيرها من الأغشية المخاطية مثل الأعضاء التناسلية التي قد تتطور الى انتشار البثور على نطاق واسع أو تقشير الجلد (متلازمة ستيفنز جونسون ، تَقَشُّرُ الأَنْسِجَةِ المُتَمَوِّتَةِ البَشْرَوِيَّةِ التَّسَمُّمِيّ).</p><p dir="RTL">تأثيرات جانبية غير معروف معدل تكرارها (لا يمكن تقديرها من واقع البيانات المتاحة)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور غير إعتيادي من ألم&nbsp; أو وخزحارق أو خدر أو ضعف العضلات في الأطراف (الإعتلال العصبي) (انظر القسم 2: تحذيرات واحتياطات)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل دوائي يسبب الطفح الجلدي، الحمى، التهاب الأعضاء الداخلية، إعتلالات دموية والأمراض الجهازية (DRESS&nbsp; متلازمة رد الفعل الدوائي المرافق كثرة اليوزينيات والاعراض الجهازية ،&nbsp; AGEP بثار الطفح الحاد المعمم&nbsp;)</p><p dir="RTL">التأثيرات الجانبية الأخرى التي لوحظت أثناء العلاج بسيبروفلوكساسين المدرجه أدناه التي يحتمل أن تكون:</p><p dir="RTL">شائعة (قد تؤثر فیما یصل إلى شخص من بین كل 10 أشخاص):</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان ، إسهال.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المفاصل والتهاب المفاصل في الأطفال.</p><p dir="RTL">غير شائعة (قد تؤثر فیما یصل إلى شخص من بین كل 100 شخص):</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المفاصل في البالغين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى فطرية إضافية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تركيز عال من اليُوزِيْنِيَّات (أحد أنواع كريات الدم البيضاء).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط النشاط أو الهياج.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع، أو دوخة، أو مشاكل في النوم أو اضطرابات بحاسة التذوق.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قيء، أو ألم في البطن، أو مشاكل متعلقة بالهضم مثل اضطراب المعدة (عسر هضم/ حموضة) أو خروج غازات( ريح).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستويات مواد معينة في الدم (ناقلات الأمين و/أو البيليروبين).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي أو حكة أو شرى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف وظائف الكُلى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العضلات والعظام أو الشعور بأنك لست على ما يرام (وهن) أو حمى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة إنزيم الفُسْفاتازِ القَلَوِيِّ في الدم (مادة معينة في الدم).</p><p dir="RTL">نادرة (قد تؤثر فیما یصل إلى شخص من بین كل 1000 شخص):</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العضلات و التهاب المفاصل و زيادة توتر العضلات و تقلصها.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأمعاء (التهاب القولون) المقترن باستعمال المضادات الحيوية (يمكن أن يؤدي إلى الوفاة في حالات نادرة جدًّا)</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (انظر قسم 2:&quot; تحذيرات وإحتياطات&quot;).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغييرات في تعداد خلايا الدم (قلة الكريات البيضاء، كثرة الكريات البيضاء، قلة العدلات، فقر الدم) أو زيادة أو انخفاض مستويات أحد عوامل تجلط الدم (الصفائح الدموية).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل حساسية، أو تورم (وذمة)، أو تورم سريع في الجلد والأغشية المخاطية (وذمة وعائية) (انظر قسم 2:&quot; تحذيرات وإحتياطات&quot;).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات سكر في الدم ( زيادة سكر الدم )</p><p dir="RTL">&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نخفاض مستوى السكر في الدم (نقص سكر الدَّم (انظر قسم 2:&quot; تحذيرات وإحتياطات&quot;).&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتباك، أو توهان، أو تفاعلات من القلق، أو أحلام غريبة، أو اكتئاب (قد يؤدي إلى أفكار انتحارية أو محاولات انتحار أو الانتحار بالفعل) (انظر قسم 2:&quot; تحذيرات وإحتياطات&quot;). &nbsp;&nbsp;أو هلَاوِس.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تنميل ووخز، أو حساسية غير معتادة لمنبهات الحواس، أو قلة حساسية الجلد، أو رعاش أو دوخة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الرؤية من بينها ازدواج الرؤية (انظر قسم 2:&quot; تحذيرات وإحتياطات&quot;).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طنين في الأذن، فقدان السمع، اضطرابات بحاسة السمع.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة ضربات القلب (تَسَرُّعُ القَلْب).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تمدد الأوعية الدموية أو انخفاض ضغط الدم أو إغماء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس، بما في ذلك أعراض الربو.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الكبد أو يرقان (يرقان ركودي) أو التهاب الكبد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حساسية تجاه الضوء (انظر قسم 2:&quot; تحذيرات وإحتياطات&quot;).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل الكلى، وجود دم أو بلورات في البول&nbsp; ، التهاب الجهاز البولي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتباس السوائل أو زيادة التعرق.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستويات إنزيم الأميلاز.</p><p dir="RTL">نادرة جدًّا (قد تؤثر فیما یصل إلى شخص من بین كل 10000 شخص):</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوع خاص من الانخفاض في عدد خلايا الدم الحمراء (فقر الدم الانحلالي)؛ انخفاض خطير في أحد أنواع كريات الدم البيضاء (ندْرَةُ المُحَبَّبات)( انظر قسم 2:&quot; تحذيرات وإحتياطات&quot;) ؛ انخفاض في عدد خلايا الدم البيضاء والحمراء والصفائح الدموية (قِلَّة الكُرَيَّاتِ الشَّامِلَة)، وقد يُؤدي ذلك إلى الوفاة، وكبت النخاع العظمي الذي قد يؤدي كذلك إلى الوفاة .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية&nbsp; تسمى تفاعلات تشبه داء المصل) (انظر قسم 2:&quot; تحذيرات وإحتياطات&quot;)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات عقلية (تفاعلات ذهانية قد تؤدي إلى أفكار انتحارية أو محاولات انتحار أو الانتحار بالفعل) (انظر قسم 2:&quot; تحذيرات وإحتياطات&quot;)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع نصفي، واضطرابات في القدرة على التنسیق الحركي ، طریقة مشي غیر مستقرة (اضطراب في طریقة المشي) ، اضطرابات في حاسة الشم ، ضغط على الدماغ (ضغط داخل القحف وورم مُخي كاذب).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اختلال في رؤية الألوان.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب جدار الأوعية الدموية (التهاب وعائي).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; موت خلايا الكبد (نخر الكبد) الذي يؤدي بصورة نادرة جدًّا إلى فشل كبدي مهدد للحياة (انظر قسم 2:&quot; تحذيرات وإحتياطات&quot;) .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف قليل بالغ الدقة أسفل الجلد (حبرات &quot;نقاط نزفيه دقيقه&quot;)، أو طفح جلدي متعدد، أو طفح جلدي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تدهور أعراض الوهن العضلي الوبيل (انظر قسم 2:&quot; تحذيرات وإحتياطات&quot;).</p><p dir="RTL">غير معروف معدل تكرارها (لا يمكن تقديرها من واقع البيانات المتاحة)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المتلازمة المرتبطة بضعف طرح المياه وانخفاض مستويات الصوديوم (متلازمة الإفراز غير الملائم للهرمون المضاد لإدرار البول SIDAH )&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بإثارة زائدة&nbsp; (الهوس) أو الشعور بتفاؤل كبير وفرط النشاط (هوس خفيف)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تسارع النظم القلبي بشكل غير طبيعي، عدم انتظام النظم القلبي بشكل مهدد للحياة، تغير في النظم القلبي (يسمى بـ &quot;إطالة فترة QT&quot;، ويمكن ملاحظته في رسم القلب أو مخطط النشاط الكهربي للقلب).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تأثيرالدواء على تجلط الدم (في المرضى الذين يتم علاجهم باستخدام مناهضات فيتامين ك).</p><p dir="RTL">إذا أصبح أيٍّ من&nbsp; التأثيرات الجانبیة خطیرًا أو لاحظت تأثيرات جانبیة غیر المدرجة في ھذه النشرة، یُرجى إبلاغ الطبیب أو الصیدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تحفظ الأدوية بعيدا عن متناول الأطفال ونظرهم. يحفظ في درجة حرارة لا تزيد عن 30 درجة مئوية في مكان جاف بعيدا عن الضوء. لا تستعمل إميسبرو بعد انقضاء تاريخ الصلاحية المدون على الشريط وعلى العبوة بعد كلمة EXP.</p><p dir="RTL">&nbsp;لا ينبغي التخلص من الأدوية في المياه العادمة أو النفايات المنزلية . إسأل الصيدلي الخاص بك عن الطريقة المناسبة للتخلص من الأدوية التي لم تعد بحاجة إليها . فمن شأن هذه الإجراءات حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي سيبروفلوكساسين.&nbsp; يحتوي كل قرص مغلف على 582 ملجم سيبروفلوكساسين هيدروكلوريد مكافئ لـ 500 ملجم سيبروفلوكساسين . المكونات الأخرى:</p><p dir="RTL">المحتوى الداخلي للقرص: نشا الذرة، وسليلوز دقيق التبلور، وكبريتات لوريل الصوديوم، وستيرات الماغنسيوم، وتلك منّقى، وسيليكا غروية لا مائية، وجليكولات نشا الصوديوم وكروسبوفيدون.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">غلاف القرص: هايبروميلوز، وبولي إيثيلين جلايكول، وثاني أكسيد التيتانيوم، ومستحلب سيميثيكون.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص بيضاوية مغلفة يميل لونها بين الابيض الى الأبيض المصفر محفور على أحد جانبيها GP27&nbsp; والجانب الاخر خال من الحفر. يتوفر في عبوات بكل منها 10 أقراص (شريط واحد به 10 أقراص مغلفة).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة جلوبال فارما ذ.م.م. ،&nbsp; ص.ب. 72168 ، دبي ، الامارات العربية المتحدة</p><p dir="RTL">هاتف: /97148090900+/&nbsp; ، بريد إلكتروني: info@globalpharma.ae</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم آخر تحديث لهذه النشرة في أبريل 2019  ( RLD 01/19)
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Emicipro 500 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 582 mg ciprofloxacin hydrochloride equivalent to 500mg ciprofloxacin.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
Each Tablets is White to off-white biconvex round film coated with “GP27” embossing on one side and plain from the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Emicipro 500 mg film-coated tablets are indicated for the treatment of the following infections (see sections 4.4 and 5.1). Special attention should be paid to available information on resistance to ciprofloxacin before commencing therapy.</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p><p><u>Adults</u></p><p>&bull; Lower respiratory tract infections due to Gram-negative bacteria</p><p>- exacerbations of chronic obstructive pulmonary disease</p><p>- broncho-pulmonary infections in cystic fibrosis or in bronchiectasis</p><p>- pneumonia</p><p>&bull; Chronic suppurative otitis media</p><p>&bull; Acute exacerbation of chronic sinusitis especially if these are caused by Gram-negative bacteria</p><p>&bull; Urinary tract infections</p><p>&bull; Genital tract infections</p><p>- gonococcal uretritis and cervicitis due to susceptible&nbsp;<em>Neisseria gonorrhoeae</em></p><p>- epididymo-orchitis including cases due to susceptible&nbsp;<em>Neisseria gonorrhoeae</em></p><p>- pelvic inflammatory disease including cases due to susceptible&nbsp;<em>Neisseria gonorrhoeae</em></p><p>&bull; Infections of the gastro-intestinal tract (e.g. travellers&#39; diarrhoea)</p><p>&bull; Intra-abdominal infections</p><p>&bull; Infections of the skin and soft tissue caused by Gram-negative bacteria</p><p>&bull; Malignant external otitis</p><p>&bull; Infections of the bones and joints</p><p>&bull; Prophylaxis of invasive infections due to&nbsp;<em>Neisseria meningitidis</em></p><p>&bull; Inhalation anthrax (post-exposure prophylaxis and curative treatment)</p><p>Ciprofloxacin may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.</p><p><u>Children and adolescents</u></p><p>&bull; Broncho-pulmonary infections in cystic fibrosis caused by&nbsp;<em>Pseudomonas aeruginosa</em></p><p>&bull; Complicated urinary tract infections and pyelonephritis</p><p>&bull; Inhalation anthrax (post-exposure prophylaxis and curative treatment)</p><p>Ciprofloxacin may also be used to treat severe infections in children and adolescents when this is considered to be necessary.</p><p>Treatment should be initiated only by physicians who are experienced in the treatment of cystic fibrosis and/or severe infections in children and adolescents (see sections 4.4 and 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>The dosage is determined by the indication, the severity and the site of the infection, the susceptibility to ciprofloxacin of the causative organism(s), the renal function of the patient and, in children and adolescents the body weight.</p><p>The duration of treatment depends on the severity of the illness and on the clinical and bacteriological course.</p><p>Treatment of infections due to certain bacteria (e.g.&nbsp;<em>Pseudomonas aeruginosa</em>,&nbsp;<em>Acinetobacter&nbsp;</em>or&nbsp;<em>Staphylococci</em>) may require higher ciprofloxacin doses and co-administration with other appropriate antibacterial agents.</p><p>Treatment of some infections (e.g. pelvic inflammatory disease, intra-abdominal infections, infections in neutropenic patients and infections of bones and joints) may require co-administration with other appropriate antibacterial agents depending on the pathogens involved.</p><p><em><u>Adults</u></em></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Indications</strong></p></td><td style="vertical-align:top"><p><strong>Daily dose in mg</strong></p></td><td style="vertical-align:top"><p><strong>Total duration of treatment (potentially including initial parenteral treatment with ciprofloxacin)</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Infections of the lower respiratory tract</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>7 to 14 days</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Infections of the upper respiratory tract</p></td><td style="vertical-align:top"><p>Acute exacerbation of chronic sinusitis</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>7 to 14 days</p></td></tr><tr><td style="vertical-align:top"><p>Chronic suppurative otitis media</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>7 to 14 days</p></td></tr><tr><td style="vertical-align:top"><p>Malignant external otitis</p></td><td style="vertical-align:top"><p>750 mg twice daily</p></td><td style="vertical-align:top"><p>28 days up to 3 months</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Urinary tract infections (see section 4.4)</p></td><td rowspan="2" style="vertical-align:top"><p>Uncomplicated cystitis</p></td><td style="vertical-align:top"><p>250 mg twice daily to 500 mg twice daily</p></td><td style="vertical-align:top"><p>3 days</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>In pre-menopausal women, 500 mg single dose may be used</p></td></tr><tr><td style="vertical-align:top"><p>Complicated cystitis, Uncomplicated pyelonephritis</p></td><td style="vertical-align:top"><p>500 mg twice daily</p></td><td style="vertical-align:top"><p>7 days</p></td></tr><tr><td style="vertical-align:top"><p>Complicated pyelonephritis</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>at least 10 days, it can be continued for longer than 21 days in some specific circumstances (such as abscesses)</p></td></tr><tr><td style="vertical-align:top"><p>Prostatitis</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>2 to 4 weeks (acute) to 4 to 6 weeks (chronic)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Genital tract infections</p></td><td style="vertical-align:top"><p>Gonococcal uretritis and cervicitis</p></td><td style="vertical-align:top"><p>500 mg as a single dose</p></td><td style="vertical-align:top"><p>1 day (single dose)</p></td></tr><tr><td style="vertical-align:top"><p>Epididymo-orchitis and pelvic inflammatory diseases</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>at least 14 days</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Infections of the gastro-intestinal tract and intra-abdominal infections</p></td><td style="vertical-align:top"><p>Diarrhoea caused by bacterial pathogens including&nbsp;<em>Shigella&nbsp;</em>spp. other than&nbsp;<em>Shigella dysenteriae</em>&nbsp;type 1 and empirical treatment of severe travellers&#39; diarrhoea</p></td><td style="vertical-align:top"><p>500 mg twice daily</p></td><td style="vertical-align:top"><p>1 day</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea caused by&nbsp;<em>Shigella dysenteriae</em>&nbsp;type 1</p></td><td style="vertical-align:top"><p>500 mg twice daily</p></td><td style="vertical-align:top"><p>5 days</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea caused by&nbsp;<em>Vibrio cholerae</em></p></td><td style="vertical-align:top"><p>500 mg twice daily</p></td><td style="vertical-align:top"><p>3 days</p></td></tr><tr><td style="vertical-align:top"><p>Typhoid fever</p></td><td style="vertical-align:top"><p>500 mg twice daily</p></td><td style="vertical-align:top"><p>7 days</p></td></tr><tr><td style="vertical-align:top"><p>Intra-abdominal infections due to Gram-negative bacteria</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>5 to 14 days</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Infections of the skin and soft tissue</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>7 to 14 days</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Bone and joint infections</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>max. of 3 months</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Neutropenic patients with fever suspected to be due to a bacterial infection.</p><p>Ciprofloxacin should be co-administered with appropriate antibacterial agent(s) in accordance to official guidance.</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>Therapy should be continued over the entire period of neutropenia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Prophylaxis of invasive infections due to&nbsp;<em>Neisseria meningitidis</em></p></td><td style="vertical-align:top"><p>500 mg as a single dose</p></td><td style="vertical-align:top"><p>1 day (single dose)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Inhalation anthrax post-exposure prophylaxis and curative treatment for persons able to receive treatment by oral route when clinically appropriate.</p><p>Drug administration should begin as soon as possible after suspected or confirmed exposure.</p></td><td style="vertical-align:top"><p>500 mg twice daily</p></td><td style="vertical-align:top"><p>60 days from the confirmation of&nbsp;<em>Bacillus anthracis</em>&nbsp;exposure</p></td></tr></tbody></table><p><em><u>Paediatric population</u></em></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Indications</strong></p></td><td style="vertical-align:top"><p><strong>Daily dose in mg</strong></p></td><td style="vertical-align:top"><p><strong>Total duration of treatment (potentially including initial parenteral treatment with ciprofloxacin)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Cystic fibrosis</p></td><td style="vertical-align:top"><p>20 mg/kg body weight twice daily with a maximum of 750 mg per dose.</p></td><td style="vertical-align:top"><p>10 to 14 days</p></td></tr><tr><td style="vertical-align:top"><p>Complicated urinary tract infections and pyelonephritis</p></td><td style="vertical-align:top"><p>10 mg/kg body weight twice daily to 20 mg/kg body weight twice daily with a maximum of 750 mg per dose.</p></td><td style="vertical-align:top"><p>10 to 21 days</p></td></tr><tr><td style="vertical-align:top"><p>Inhalation anthrax post-exposure prophylaxis and curative treatment for persons able to receive treatment by oral route when clinically appropriate. Drug administration should begin as soon as possible after suspected or confirmed exposure.</p></td><td style="vertical-align:top"><p>10 mg/kg body weight twice daily to 15 mg/kg body weight twice daily with a maximum of 500 mg per dose.</p></td><td style="vertical-align:top"><p>60 days from the confirmation of&nbsp;<em>Bacillus anthracis</em>&nbsp;exposure</p></td></tr><tr><td style="vertical-align:top"><p>Other severe infections</p></td><td style="vertical-align:top"><p>20 mg/kg body weight twice daily with a maximum of 750 mg per dose.</p></td><td style="vertical-align:top"><p>According to the type of infections</p></td></tr></tbody></table><p><em><u>Elderly patients</u></em></p><p>Elderly patients should receive a dose selected according to the severity of the infection and the patient&#39;s creatinine clearance.</p><p><em><u>Patients with renal and hepatic impairment</u></em></p><p>Recommended starting and maintenance doses for patients with impaired renal function:</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Creatinine Clearance</strong></p><p><strong>[mL/min/1.73 m</strong><strong><sup>2</sup></strong><strong>]</strong></p></td><td style="vertical-align:top"><p><strong>Serum Creatinine</strong></p><p><strong>[&micro;mol/L]</strong></p></td><td style="vertical-align:top"><p><strong>Oral Dose</strong></p><p><strong>[mg]</strong></p></td></tr><tr><td style="vertical-align:top"><p>&gt; 60</p></td><td style="vertical-align:top"><p>&lt; 124</p></td><td style="vertical-align:top"><p>See Usual Dosage.</p></td></tr><tr><td style="vertical-align:top"><p>30-60</p></td><td style="vertical-align:top"><p>124 to 168</p></td><td style="vertical-align:top"><p>250-500 mg every 12 h</p></td></tr><tr><td style="vertical-align:top"><p>&lt; 30</p></td><td style="vertical-align:top"><p>&gt; 169</p></td><td style="vertical-align:top"><p>250-500 mg every 24 h</p></td></tr><tr><td style="vertical-align:top"><p>Patients on haemodialysis</p></td><td style="vertical-align:top"><p>&gt; 169</p></td><td style="vertical-align:top"><p>250-500 mg every 24 h (after dialysis)</p></td></tr><tr><td style="vertical-align:top"><p>Patients on peritoneal dialysis</p></td><td style="vertical-align:top"><p>&gt; 169</p></td><td style="vertical-align:top"><p>250-500 mg every 24 h</p></td></tr></tbody></table><p>In patients with impaired liver function no dose adjustment is required.</p><p>Dosing in children with impaired renal and/or hepatic function has not been studied.</p><p><u>Method of administration</u></p><p>Tablets are to be swallowed unchewed with fluid. They can be taken independent of mealtimes. If taken on an empty stomach, the active substance is absorbed more rapidly. Ciprofloxacin tablets should not be taken with dairy products (e.g. milk, yoghurt) or mineral-fortified fruit-juice (e.g. calcium-fortified orange juice) (see section 4.5).</p><p>In severe cases or if the patient is unable to take tablets (e.g. patients on enteral nutrition), it is recommended to commence therapy with intravenous ciprofloxacin until a switch to oral administration is possible.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to the active substance, to other quinolones or to any of the excipients listed in section 6.1.
• Concomitant administration of ciprofloxacin and tizanidine (see section 4.5).


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Severe infections and mixed infections with Gram-positive and anaerobic pathogens</u></p><p>Ciprofloxacin monotherapy is not suited for treatment of severe infections and infections that might be due to Gram-positive or anaerobic pathogens. In such infections ciprofloxacin must be co-administered with other appropriate antibacterial agents.</p><p><u>Streptococcal Infections (including Streptococcus pneumoniae)</u></p><p>Ciprofloxacin is not recommended for the treatment of streptococcal infections due to inadequate efficacy<em>.</em></p><p><u>Genital tract infections</u></p><p>Gonococcal uretritis, cervicitis, epididymo-orchitis and pelvic inflammatory diseases may be caused by fluoroquinolone-resistant&nbsp;<em>Neisseria gonorrhoeae</em>&nbsp;isolates.</p><p>Therefore, ciprofloxacin should be administered for the treatment of gonococcal uretritis or cervicitis only if ciprofloxacin-resistant&nbsp;<em>Neisseria gonorrhoeae</em>&nbsp;can be excluded.</p><p>For epididymo-orchitis and pelvic inflammatory diseases, empirical ciprofloxacin should only be considered in combination with another appropriate antibacterial agent (e.g. a cephalosporin) unless ciprofloxacin-resistant&nbsp;<em>Neisseria gonorrhoeae</em>&nbsp;can be excluded. If clinical improvement is not achieved after 3 days of treatment, the therapy should be reconsidered.</p><p><u>Urinary tract infections</u></p><p>Resistance to fluoroquinolones of&nbsp;<em>Escherichia coli&nbsp;</em>&ndash; the most common pathogen involved in urinary tract infections &ndash; varies across the European Union. Prescribers are advised to take into account the local prevalence of resistance in&nbsp;<em>Escherichia coli</em>&nbsp;to fluoroquinolones.</p><p>The single dose of ciprofloxacin that may be used in uncomplicated cystitis in pre-menopausal women is expected to be associated with lower efficacy than the longer treatment duration. This is all the more to be taken into account as regards the increasing resistance level of&nbsp;<em>Escherichia coli</em>&nbsp;to quinolones.</p><p><u>Intra-abdominal infections</u></p><p>There are limited data on the efficacy of ciprofloxacin in the treatment of post-surgical intra-abdominal infections.</p><p><u>Travellers&#39; diarrhoea</u></p><p>The choice of ciprofloxacin should take into account information on resistance to ciprofloxacin in relevant pathogens in the countries visited.</p><p><u>Infections of the bones and joints</u></p><p>Ciprofloxacin should be used in combination with other antimicrobial agents depending on the results of the microbiological documentation.</p><p><u>Inhalational anthrax</u></p><p>Use in humans is based on&nbsp;<em>in-vitro</em>&nbsp;susceptibility data and on animal experimental data together with limited human data. Treating physicians should refer to national and/or international consensus documents regarding the treatment of anthrax.</p><p><u>Paediatric population</u></p><p>The use of ciprofloxacin in children and adolescents should follow available official guidance. Ciprofloxacin treatment should be initiated only by physicians who are experienced in the treatment of cystic fibrosis and/or severe infections in children and adolescents.</p><p>Ciprofloxacin has been shown to cause arthropathy in weight-bearing joints of immature animals. Safety data from a randomised double-blind study on ciprofloxacin use in children (ciprofloxacin: n=335, mean age = 6.3 years; comparators: n=349, mean age = 6.2 years; age range = 1 to 17 years) revealed an incidence of suspected drug-related arthropathy (discerned from joint-related clinical signs and symptoms) by Day +42 of 7.2% and 4.6%. Respectively, an incidence of drug-related arthropathy by 1-year follow-up was 9.0% and 5.7%. The increase of suspected drug-related arthropathy cases over time was not statistically significant between groups. Treatment should be initiated only after a careful benefit/risk evaluation, due to possible adverse events related to joints and/or surrounding tissue (see section 4.8).</p><p><em>Broncho-pulmonary infections in cystic fibrosis</em></p><p>Clinical trials have included children and adolescents aged 5-17 years. More limited experience is available in treating children between 1 and 5 years of age.</p><p><em>Complicated urinary tract infections and pyelonephritis</em></p><p>Ciprofloxacin treatment of urinary tract infections should be considered when other treatments cannot be used, and should be based on the results of the microbiological documentation.</p><p>Clinical trials have included children and adolescents aged 1-17 years.</p><p><em>Other specific severe infections</em></p><p>Other severe infections in accordance with official guidance, or after careful benefit-risk evaluation when other treatments cannot be used, or after failure to conventional therapy and when the microbiological documentation can justify a ciprofloxacin use.</p><p>The use of ciprofloxacin for specific severe infections other than those mentioned above has not been evaluated in clinical trials and the clinical experience is limited. Consequently, caution is advised when treating patients with these infections.</p><p><u>Hypersensitivity</u></p><p>Hypersensitivity and allergic reactions, including anaphylaxis and anaphylactoid reactions, may occur following a single dose (see section 4.8) and may be life-threatening. If such reaction occurs, ciprofloxacin should be discontinued and an adequate medical treatment is required.</p><p><u>Musculoskeletal System</u></p><p>Ciprofloxacin should generally not be used in patients with a history of tendon disease/disorder related to quinolone treatment. Nevertheless, in very rare instances, after microbiological documentation of the causative organism and evaluation of the risk/benefit balance, ciprofloxacin may be prescribed to these patients for the treatment of certain severe infections, particularly in the event of failure of the standard therapy or bacterial resistance, where the microbiological data may justify the use of ciprofloxacin.</p><p>Tendinitis and tendon rupture (especially Achilles tendon), sometimes bilateral, may occur with ciprofloxacin, even within the first 48 hours of treatment. Inflammation and ruptures of tendon may occur even up to several months after discontinuation of ciprofloxacin therapy. The risk of tendinopathy may be increased in elderly patients or in patients concomitantly treated with corticosteroids (see section 4.8).</p><p>At any sign of tendinitis (e.g. painful swelling, inflammation), ciprofloxacin treatment should be discontinued. Care should be taken to keep the affected limb at rest.</p><p>Ciprofloxacin should be used with caution in patients with myasthenia gravis, because symptoms can be exacerbated (see section 4.8).</p><p><u>Aortic aneurysm and dissection</u></p><p>Epidemiologic studies report an increased risk of aortic aneurysm and dissection after intake of fluoroquinolones, particularly in the older population.</p><p>Therefore, fluoroquinolones should only be used after careful benefit-risk assessment and after consideration of other therapeutic options in patients with positive family history of aneurysm disease, or in patients diagnosed with pre-existing aortic aneurysm and/or dissection, or in presence of other risk factors or conditions predisposing for aortic aneurysm and dissection (e.g. Marfan syndrome, vascular Ehlers-Danlos syndrome, Takayasu arteritis, giant cell arteritis, Behcet&#39;s disease, hypertension, known atherosclerosis).</p><p>In case of sudden abdominal, chest or back pain, patients should be advised to immediately consult a physician in an emergency department.</p><p><u>Vision disorders</u></p><p>If vision becomes impaired or any effects on the eyes are experienced, an eye specialist should be consulted immediately.</p><p><u>Photosensitivity</u></p><p>Ciprofloxacin has been shown to cause photosensitivity reactions. Patients taking ciprofloxacin should be advised to avoid direct exposure to either extensive sunlight or UV irradiation during treatment (see section 4.8).</p><p><u>Central Nervous System</u></p><p>Ciprofloxacin like other quinolones are known to trigger seizures or lower the seizure threshold. Cases of status epilepticus have been reported. Ciprofloxacin should be used with caution in patients with CNS disorders which may be predisposed to seizure. If seizures occur ciprofloxacin should be discontinued (see section 4.8). Psychiatric reactions may occur even after first administration of ciprofloxacin. In rare cases, depression or psychosis can progress to suicidal ideations/thoughts culminating in attempted suicide or completed suicide. In the occurrence of such cases, ciprofloxacin should be discontinued.</p><p>Cases of polyneuropathy (based on neurological symptoms such as pain, burning, sensory disturbances or muscle weakness, alone or in combination) have been reported in patients receiving ciprofloxacin. Ciprofloxacin should be discontinued in patients experiencing symptoms of neuropathy, including pain, burning, tingling, numbness, and/or weakness in order to prevent the development of an irreversible condition (see section 4.8).</p><p><u>Cardiac disorders</u></p><p>Caution should be taken when using fluoroquinolones, including ciprofloxacin, in patients with known risk factors for prolongation of the QT interval such as, for example:</p><p>&bull; congenital long QT syndrome</p><p>&bull; concomitant use of drugs that are known to prolong the QT interval (e.g. Class IA and III anti-arrhythmics, tricyclic antidepressants, macrolides, antipsychotics)</p><p>&bull; uncorrected electrolyte imbalance (e.g. hypokalaemia, hypomagnesaemia)</p><p>&bull; cardiac disease (e.g. heart failure, myocardial infarction, bradycardia)</p><p>Elderly patients and women may be more sensitive to QTc-prolonging medications. Therefore, caution should be taken when using fluoroquinolones, including ciprofloxacin, in these populations.</p><p>(See section 4.2 Elderly patients, section 4.5, section 4.8, section 4.9).</p><p><u>Dysglycaemia</u></p><p>As with all quinolones, disturbances in blood glucose, including both hypoglycaemia and hyperglycaemia have been reported (see section 4.8), usually in elderly diabetic patients, receiving concomitant treatment with an oral hypoglycaemic agent (e.g. glibenclamide) or with insulin. Cases of hypoglycaemic coma have been reported. In diabetic patients, careful monitoring of blood glucose is recommended.</p><p><u>Gastrointestinal System</u></p><p>The occurrence of severe and persistent diarrhoea during or after treatment (including several weeks after treatment) may indicate an antibiotic-associated colitis (life-threatening with possible fatal outcome), requiring immediate treatment (see section 4.8). In such cases, ciprofloxacin should immediately be discontinued, and an appropriate therapy initiated. Anti-peristaltic drugs are contraindicated in this situation.</p><p><u>Renal and urinary system</u></p><p>Crystalluria related to the use of ciprofloxacin has been reported (see section 4.8). Patients receiving ciprofloxacin should be well hydrated and excessive alkalinity of the urine should be avoided.</p><p><u>Impaired renal function</u></p><p>Since ciprofloxacin is largely excreted unchanged via renal pathway dose adjustment is needed in patients with impaired renal function as described in section 4.2 to avoid an increase in adverse drug reactions due to accumulation of ciprofloxacin.</p><p><u>Hepatobiliary system</u></p><p>Cases of hepatic necrosis and life-threatening hepatic failure have been reported with ciprofloxacin (see section 4.8). In the event of any signs and symptoms of hepatic disease (such as anorexia, jaundice, dark urine, pruritus, or tender abdomen), treatment should be discontinued.</p><p><u>Glucose-6-phosphate dehydrogenase deficiency</u></p><p>Haemolytic reactions have been reported with ciprofloxacin in patients with glucose-6-phosphate dehydrogenase deficiency. Ciprofloxacin should be avoided in these patients unless the potential benefit is considered to outweigh the possible risk. In this case, potential occurrence of haemolysis should be monitored.</p><p><u>Resistance</u></p><p>During or following a course of treatment with ciprofloxacin bacteria that demonstrate resistance to ciprofloxacin may be isolated, with or without a clinically apparent superinfection. There may be a particular risk of selecting for ciprofloxacin-resistant bacteria during extended durations of treatment and when treating nosocomial infections and/or infections caused by&nbsp;<em>Staphylococcus</em>&nbsp;and&nbsp;<em>Pseudomonas</em>&nbsp;species.</p><p><u>Cytochrome P450</u></p><p>Ciprofloxacin inhibits CYP1A2 and thus may cause increased serum concentration of concomitantly administered substances metabolised by this enzyme (e.g. theophylline, clozapine, olanzapine, ropinirole, tizanidine, duloxetine, agomelatine). Therefore, patients taking these substances concomitantly with ciprofloxacin should be monitored closely for clinical signs of overdose, and determination of serum concentrations (e.g. of theophylline) may be necessary (see section 4.5). Co-administration of ciprofloxacin and tizanidine is contra-indicated.</p><p><u>Methotrexate</u></p><p>The concomitant use of ciprofloxacin with methotrexate is not recommended (see section 4.5).</p><p><u>Interaction with tests</u></p><p>The&nbsp;<em>in-vitro</em>&nbsp;activity of ciprofloxacin against&nbsp;<em>Mycobacterium tuberculosis</em>&nbsp;might give false negative bacteriological test results in specimens from patients currently taking ciprofloxacin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Effects of other products on ciprofloxacin:</u></p><p><em><u>Drugs known to prolong QT interval</u></em></p><p>Ciprofloxacin, like other fluoroquinolones, should be used with caution in patients receiving drugs known to prolong QT interval (e.g. Class IA and III anti-arrhythmics, tricyclic antidepressants, macrolides, antipsychotics) (see section 4.4).</p><p><em><u>Chelation Complex Formation</u></em></p><p>The simultaneous administration of ciprofloxacin (oral) and multivalent cation-containing drugs and mineral supplements (e.g. calcium, magnesium, aluminium, iron), polymeric phosphate binders (e.g. sevelamer or lanthanum carbonate), sucralfate or antacids, and highly buffered drugs (e.g. didanosine tablets) containing magnesium, aluminium, or calcium reduces the absorption of ciprofloxacin. Consequently, ciprofloxacin should be administered either 1-2 hours before or at least 4 hours after these preparations. The restriction does not apply to antacids belonging to the class of H2 receptor blockers.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Food and Dairy Products</u></em></p><p>Dietary calcium as part of a meal does not significantly affect absorption. However, the concurrent administration of dairy products or mineral-fortified drinks alone (e.g. milk, yoghurt, calcium-fortified orange juice) with ciprofloxacin should be avoided because absorption of ciprofloxacin may be reduced.</p><p><em><u>Probenecid</u></em></p><p>Probenecid interferes with renal secretion of ciprofloxacin. Co-administration of probenecid and ciprofloxacin increases ciprofloxacin serum concentrations.</p><p><em><u>Metoclopramide</u></em></p><p>Metoclopramide accelerates the absorption of ciprofloxacin (oral) resulting in a shorter time to reach maximum plasma concentrations. No effect was seen on the bioavailability of ciprofloxacin.</p><p><em><u>Omeprazole</u></em></p><p>Concomitant administration of ciprofloxacin and omeprazole containing medicinal products results in a slight reduction of C<sub>max</sub>&nbsp;and AUC of ciprofloxacin.</p><p><u>Effects of ciprofloxacin on other medicinal products:</u></p><p><em><u>Tizanidine</u></em></p><p>Tizanidine must not be administered together with ciprofloxacin (see section 4.3). In a clinical study with healthy subjects, there was an increase in serum tizanidine concentration (C<sub>max</sub>&nbsp;increase: 7-fold, range: 4 to 21-fold; AUC increase: 10-fold, range: 6 to 24-fold) when given concomitantly with ciprofloxacin. Increased serum tizanidine concentration is associated with a potentiated hypotensive and sedative effect.</p><p><em><u>Methotrexate</u></em></p><p>Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of methotrexate and increased risk of methotrexate-associated toxic reactions. The concomitant use is not recommended (see section 4.4).</p><p><em><u>Theophylline</u></em></p><p>Concurrent administration of ciprofloxacin and theophylline can cause an undesirable increase in serum theophylline concentration. This can lead to theophylline-induced side effects that may rarely be life threatening or fatal. During the combination, serum theophylline concentrations should be checked and the theophylline dose reduced as necessary (see section 4.4).</p><p><em><u>Other xanthine derivatives</u></em></p><p>On concurrent administration of ciprofloxacin and caffeine or pentoxifylline (oxpentifylline), raised serum concentrations of these xanthine derivatives were reported.</p><p><em><u>Phenytoin</u></em></p><p>Simultaneous administration of ciprofloxacin and phenytoin may result in increased or reduced serum levels of phenytoin such that monitoring of drug levels is recommended.</p><p><em><u>Cyclosporin</u></em></p><p>A transient rise in the concentration of serum creatinine was observed when ciprofloxacin and cyclosporin containing medicinal products were administered simultaneously. Therefore, it is frequently (twice a week) necessary to control the serum creatinine concentrations in these patients.</p><p><em><u>Vitamin K antagonists</u></em></p><p>Simultaneous administration of ciprofloxacin with a vitamin K antagonist may augment its anti-coagulant effects. The risk may vary with the underlying infection, age and general status of the patient so that the contribution of ciprofloxacin to the increase in INR (international normalised ratio) is difficult to assess. The INR should be monitored frequently during and shortly after co-administration of ciprofloxacin with a vitamin K antagonist (e.g., warfarin, acenocoumarol, phenprocoumon, or fluindione).</p><p><em><u>Duloxetine</u></em></p><p>In clinical studies, it was demonstrated that concomitant use of duloxetine with strong inhibitors of the CYP450 1A2 isozyme such as fluvoxamine, may result in an increase of AUC and C<sub>max</sub>&nbsp;of duloxetine. Although no clinical data are available on a possible interaction with ciprofloxacin, similar effects can be expected upon concomitant administration (see section 4.4).</p><p><em><u>Ropinirole</u></em></p><p>It was shown in a clinical study that concomitant use of ropinirole with ciprofloxacin, a moderate inhibitor of the CYP450 1A2 isozyme, results in an increase of C<sub>max</sub>&nbsp;and AUC of ropinirole by 60% and 84%, respectively. Monitoring of ropinirole-related side effects and dose adjustment as appropriate is recommended during and shortly after co-administration with ciprofloxacin (see section 4.4).</p><p><em><u>Lidocaine</u></em></p><p>It was demonstrated in healthy subjects that concomitant use of lidocaine containing medicinal products with ciprofloxacin, a moderate inhibitor of CYP450 1A2 isozyme, reduces clearance of intravenous lidocaine by 22%. Although lidocaine treatment was well tolerated, a possible interaction with ciprofloxacin associated with side effects may occur upon concomitant administration.</p><p><em><u>Clozapine</u></em></p><p>Following concomitant administration of 250 mg ciprofloxacin with clozapine for 7 days, serum concentrations of clozapine and N-desmethylclozapine were increased by 29% and 31%, respectively. Clinical surveillance and appropriate adjustment of clozapine dosage during and shortly after co-administration with ciprofloxacin are advised (see section 4.4).</p><p><em><u>Sildenafil</u></em></p><p>C<sub>max</sub>&nbsp;and AUC of sildenafil were increased approximately twofold in healthy subjects after an oral dose of 50 mg given concomitantly with 500 mg ciprofloxacin. Therefore, caution should be used prescribing ciprofloxacin concomitantly with sildenafil taking into consideration the risks and the benefits.</p><p><em><u>Agomelatine</u></em></p><p>In clinical studies, it was demonstrated that fluvoxamine, as a strong inhibitor of the CYP450 1A2 isoenzyme, markedly inhibits the metabolism of agomelatine resulting in a 60-fold increase of agomelatine exposure. Although no clinical data are available for a possible interaction with ciprofloxacin, a moderate inhibitor of CYP450 1A2, similar effects can be expected upon concomitant administration (see &#39;Cytochrome P450&#39; in section 4.4).</p><p><em><u>Zolpidem</u></em></p><p>Co-administration of ciprofloxacin may increase blood levels of zolpidem, concurrent use is not recommended</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>The data that are available on administration of ciprofloxacin to pregnant women indicates no malformative or feto/neonatal toxicity of ciprofloxacin. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. In juvenile and prenatal animals exposed to quinolones, effects on immature cartilage have been observed, thus, it cannot be excluded that the drug could cause damage to articular cartilage in the human immature organism / foetus (see section 5.3).</p><p>As a precautionary measure, it is preferable to avoid the use of ciprofloxacin during pregnancy.</p><p><u>Breast-feeding</u></p><p>Ciprofloxacin is excreted in breast milk. Due to the potential risk of articular damage, ciprofloxacin should not be used during breast-feeding.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Due to its neurological effects, ciprofloxacin may affect reaction time. Thus, the ability to drive or to operate machinery may be impaired.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most commonly reported adverse drug reactions (ADRs) are nausea and diarrhoea.</p><p>ADRs derived from clinical studies and post-marketing surveillance with ciprofloxacin (oral, intravenous, and sequential therapy) sorted by categories of frequency are listed below. The frequency analysis takes into account data from both oral and intravenous administration of ciprofloxacin.</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p>&ge; 1/100 to &lt; 1/10</p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p>&ge; 1/1,000 to &lt; 1/100</p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p>&ge; 1/10,000 to &lt; 1/1,000</p></td><td style="vertical-align:top"><p><strong>Very Rare</strong></p><p>&lt; 1/10,000</p></td><td style="vertical-align:top"><p><strong>Frequency not known</strong></p><p>(cannot be estimated from the available data)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and Infestations</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Mycotic super-infections</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Blood and Lymphatic System Disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Eosinophilia</p></td><td style="vertical-align:top"><p>Leukopenia</p><p>Anaemia</p><p>Neutropenia</p><p>Leukocytosis</p><p>Thrombocytopenia</p><p>Thrombocytaemia</p></td><td style="vertical-align:top"><p>Haemolytic anaemia</p><p>Agranulocytosis</p><p>Pancytopenia (life-threatening)</p><p>Bone marrow depression (life-threatening)</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Immune System Disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Allergic reaction</p><p>Allergic oedema / angiooedema</p></td><td style="vertical-align:top"><p>Anaphylactic reaction</p><p>Anaphylactic shock (life-threatening) (see section 4.4)</p><p>Serum sickness-like reaction</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Endocrine disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Syndrome of inappropriate secretion of antidiuretic hormone (SIADH)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and Nutrition Disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Decreased appetite</p></td><td style="vertical-align:top"><p>Hyperglycaemia</p><p>Hypoglycaemia (see section 4.4)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric Disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Psychomotor hyperactivity / agitation</p></td><td style="vertical-align:top"><p>Confusion and disorientation</p><p>Anxiety reaction</p><p>Abnormal dreams</p><p>Depression (potentially culminating in suicidal ideations/thoughts or suicide attempts and completed suicide) (see section 4.4)</p><p>Hallucinations</p></td><td style="vertical-align:top"><p>Psychotic reactions (potentially culminating in suicidal ideations/ thoughts or suicide attempts and completed suicide) (see section 4.4)</p></td><td style="vertical-align:top"><p>Mania, incl. hypomania</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous System Disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Headache</p><p>Dizziness</p><p>Sleep disorders</p><p>Taste disorders</p></td><td style="vertical-align:top"><p>Par- and Dysaesthesia</p><p>Hypoaesthesia</p><p>Tremor</p><p>Seizures (including status epilepticus see section 4.4)</p><p>Vertigo</p></td><td style="vertical-align:top"><p>Migraine</p><p>Disturbed coordination</p><p>Gait disturbance</p><p>Olfactory nerve disorders</p><p>Intracranial hypertension and pseudotumor cerebri)</p></td><td style="vertical-align:top"><p>Peripheral neuropathy and polyneuropathy (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye Disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Visual disturbances (e.g. diplopia)</p></td><td style="vertical-align:top"><p>Visual colour distortions</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Ear and Labyrinth Disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Tinnitus</p><p>Hearing loss / Hearing impaired</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac Disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Tachycardia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Ventricular arrhythmia and torsades de pointes (reported predominantly in patients with risk factors for QT prolongation), ECG QT prolonged (see sections 4.4 and 4.9)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular Disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Vasodilatation</p><p>Hypotension</p><p>Syncope</p></td><td style="vertical-align:top"><p>Vasculitis</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, Thoracic and Mediastinal Disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Dyspnoea (including asthmatic condition)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal Disorders</strong></p></td><td style="vertical-align:top"><p>Nausea</p><p>Diarrhoea</p></td><td style="vertical-align:top"><p>Vomiting</p><p>Gastrointestinal and abdominal pains</p><p>Dyspepsia</p><p>Flatulence</p></td><td style="vertical-align:top"><p>Antibiotic associated colitis (very rarely with possible fatal outcome) (see section 4.4)</p></td><td style="vertical-align:top"><p>Pancreatitis</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary Disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Increase in transaminases</p><p>Increased bilirubin</p></td><td style="vertical-align:top"><p>Hepatic impairment</p><p>Cholestatic icterus</p><p>Hepatitis</p></td><td style="vertical-align:top"><p>Liver necrosis (very rarely progressing to life-threatening hepatic failure) (see section 4.4)</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Skin and Subcutaneous Tissue Disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rash</p><p>Pruritus</p><p>Urticaria</p></td><td style="vertical-align:top"><p>Photosensitivity reactions (see section 4.4)</p></td><td style="vertical-align:top"><p>Petechiae</p><p>Erythema multiforme</p><p>Erythema nodosum</p><p>Stevens-Johnson syndrome (potentially life-threatening)</p><p>Toxic epidermal necrolysis (potentially life-threatening)</p></td><td style="vertical-align:top"><p>Acute Generalised Exanthematous Pustulosis (AGEP)</p><p>Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculo-skeletal and Connective Tissue Disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Musculo-skeletal pain (e.g. extremity pain, back pain, chest pain)</p><p>Arthralgia</p></td><td style="vertical-align:top"><p>Myalgia</p><p>Arthritis</p><p>Increased muscle tone and cramping</p></td><td style="vertical-align:top"><p>Muscular weakness</p><p>Tendinitis</p><p>Tendon rupture (predominantly Achilles tendon) (see section 4.4)</p><p>Exacerbation of symptoms of myasthenia gravis (see section 4.4)</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Renal and Urinary Disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Renal impairment</p></td><td style="vertical-align:top"><p>Renal failure</p><p>Haematuria</p><p>Crystalluria (see section 4.4)</p><p>Tubulointerstitial nephritis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>General Disorders and Administration Site Conditions</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Asthenia</p><p>Fever</p></td><td style="vertical-align:top"><p>Oedema</p><p>Sweating (hyperhidrosis)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Increase in blood alkaline phosphatase</p></td><td style="vertical-align:top"><p>Increased amylase</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>International normalised ratio increased (in patients treated with Vitamin K antagonists)</p></td></tr></tbody></table><p><u>Paediatric population</u></p><p>The incidence of arthropathy (arthralgia, arthritis), mentioned above, is referring to data collected in studies with adults. In children, arthropathy is reported to occur commonly (see section 4.4).</p><p><strong><u>Reporting of suspected adverse reactions</u></strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at:</p><p>&bull; Saudi Arabia: The National Pharmacovigilance and Drug Safety Centre (NPC) ,</p><p>Fax: +966-11-205-7662, Call NPC at +966-11-2038222, Exts 2317-2356-2340. Reporting Hotline: 19999,</p><p>E-mail: npc.drug@sfda.gov.sa , Website: www.sfda.gov.sa/npc</p><p>&bull; Other GCC States: Please contact the relevant competent authority</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>An overdose of 12 g has been reported to lead to mild symptoms of toxicity. An acute overdose of 16 g has been reported to cause acute renal failure.</p><p>Symptoms in overdose consist of dizziness, tremor, headache, tiredness, seizures, hallucinations, confusion, abdominal discomfort, renal and hepatic impairment as well as crystalluria and haematuria. Reversible renal toxicity has been reported.</p><p>Apart from routine emergency measures, e.g. ventricular emptying followed by medical carbon, it is recommended to monitor renal function, including urinary pH and acidify, if required, to prevent crystalluria. Patients should be kept well hydrated. Calcium or magnesium containing antacids may theoretically reduce the absorption of ciprofloxacin in overdoses</p><p>Only a small quantity of ciprofloxacin (&lt;10%) is eliminated by haemodialysis or peritoneal dialysis.</p><p>In the event of overdose, symptomatic treatment should be implemented ECG monitoring should be undertaken, because of the possibility of QT interval prolongation.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Fluoroquinolones, ATC code: J01MA02</p><p><u>Mechanism of action:</u></p><p>As a fluoroquinolone antibacterial agent, the bactericidal action of ciprofloxacin results from the inhibition of both type II topoisomerase (DNA-gyrase) and topoisomerase IV, required for bacterial DNA replication, transcription, repair and recombination.</p><p><u>Pharmacokinetic/pharmacodynamic relationship relationship</u></p><p>Efficacy mainly depends on the relation between the maximum concentration in serum (C<sub>max</sub>) and the minimum inhibitory concentration (MIC) of ciprofloxacin for a bacterial pathogen and the relation between the area under the curve (AUC) and the MIC.</p><p><u>Mechanism of resistance</u></p><p><em>In-vitro&nbsp;</em>resistance to ciprofloxacin can be acquired through a stepwise process by target site mutations in both DNA gyrase and topoisomerase IV. The degree of cross-resistance between ciprofloxacin and other fluoroquinolones that results is variable. Single mutations may not result in clinical resistance, but multiple mutations generally result in clinical resistance to many or all active substances within the class.</p><p>Impermeability and/or active substance efflux pump mechanisms of resistance may have a variable effect on susceptibility to fluoroquinolones, which depends on the physiochemical properties of the various active substances within the class and the affinity of transport systems for each active substance. All&nbsp;<em>in-vitro&nbsp;</em>mechanisms of resistance are commonly observed in clinical isolates. Resistance mechanisms that inactivate other antibiotics such as permeation barriers (common in&nbsp;<em>Pseudomonas aeruginosa</em>) and efflux mechanisms may affect susceptibility to ciprofloxacin.</p><p>Plasmid-mediated resistance encoded by qnr-genes has been reported.</p><p><u>Spectrum of antibacterial activity</u></p><p>Breakpoints separate susceptible strains from strains with intermediate susceptibility and the latter from resistant strains:</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>EUCAST Recommendations</u></em></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Microorganisms</strong></p></td><td style="vertical-align:top"><p><strong>Susceptible</strong></p></td><td style="vertical-align:top"><p><strong>Resistant</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Enterobacteriaceae</em></p></td><td style="vertical-align:top"><p>S &le; 0.25 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 0.5 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Salmonella spp.</em></p></td><td style="vertical-align:top"><p>S &le; 0.06 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 0.06 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Pseudomonas&nbsp;</em>spp.</p></td><td style="vertical-align:top"><p>S &le; 0.5 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 0.5 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Acinetobacter&nbsp;</em>spp.</p></td><td style="vertical-align:top"><p>S &le; 1 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 1 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus&nbsp;</em>spp.<sup>1</sup></p></td><td style="vertical-align:top"><p>S &le; 1 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 1 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus influenzae</em></p></td><td style="vertical-align:top"><p>S &le; 0.06 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 0.06 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Moraxella catarrhalis</em></p></td><td style="vertical-align:top"><p>S &le; 0.125 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 0.125 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Neisseria gonorrhoeae</em></p></td><td style="vertical-align:top"><p>S &le; 0.03 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 0.06 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Neisseria meningitidis</em></p></td><td style="vertical-align:top"><p>S &le; 0.03 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 0.03 mg/L</p></td></tr><tr><td style="vertical-align:top"><p>Non-species-related breakpoints<strong>*</strong></p></td><td style="vertical-align:top"><p>S &le; 0.25 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 0.5 mg/L</p></td></tr></tbody></table><p>1&nbsp;<em>Staphylococcus</em>&nbsp;spp. - breakpoints for ciprofloxacin relate to high dose therapy.</p><p>* Non-species-related breakpoints have been determined mainly on the basis of PK/PD data and are independent of MIC distributions of specific species. They are for use only for species that have not been given a species-specific breakpoint and not for those species where susceptibility testing is not recommended.</p><p>The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.</p><p>Groupings of relevant species according to ciprofloxacin susceptibility (for&nbsp;<em>Streptococcus</em>&nbsp;species see section 4.4).</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>COMMONLY SUSCEPTIBLE SPECIES</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-positive micro-organisms</u></p><p><em>Bacillus anthracis</em>&nbsp;(1)</p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-negative micro-organisms</u></p><p><em>Aeromonas&nbsp;</em>spp.</p><p><em>Brucella&nbsp;</em>spp.</p><p><em>Citrobacter koseri</em></p><p><em>Francisella tularensis</em></p><p><em>Haemophilus ducreyi</em></p><p><em>Haemophilus influenzae*</em></p><p><em>Legionella&nbsp;</em>spp.</p><p><em>Moraxella catarrhalis*</em></p><p><em>Neisseria meningitidis</em></p><p><em>Pasteurella&nbsp;</em>spp.</p><p><em>Salmonella&nbsp;</em>spp.<em>*</em></p><p><em>Shigella&nbsp;</em>spp.<em>*</em></p><p><em>Vibrio&nbsp;</em>spp.</p><p><em>Yersinia pestis</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Anaerobic micro-organisms</u></p><p><em>Mobiluncus</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Other micro-organisms</u></p><p><em>Chlamydia trachomatis&nbsp;</em>($)</p><p><em>Chlamydia pneumoniae&nbsp;</em>($)</p><p><em>Mycoplasma hominis&nbsp;</em>($)</p><p><em>Mycoplasma pneumoniae&nbsp;</em>($)</p></td></tr><tr><td style="vertical-align:top"><p><strong>SPECIES FOR WHICH ACQUIRED RESISTANCE MAY BE A PROBLEM</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-positive micro-organisms</u></p><p><em>Enterococcus faecalis&nbsp;</em>($)</p><p><em>Staphylococcus&nbsp;</em>spp.<em>*&nbsp;</em>(2)</p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-negative micro-organisms</u></p><p><em>Acinetobacter baumannii</em><em><sup>+</sup></em></p><p><em>Burkholderia cepacia</em><em><sup>+</sup></em><em>*</em></p><p><em>Campylobacter&nbsp;</em>spp.<em><sup>+</sup></em><em>*</em></p><p><em>Citrobacter freundii*</em></p><p><em>Enterobacter aerogenes</em></p><p><em>Enterobacter cloacae*</em></p><p><em>Escherichia coli*</em></p><p><em>Klebsiella oxytoca</em></p><p><em>Klebsiella pneumoniae*</em></p><p><em>Morganella morganii*</em></p><p><em>Neisseria gonorrhoeae*</em></p><p><em>Proteus mirabilis*</em></p><p><em>Proteus vulgaris*</em></p><p><em>Providencia&nbsp;</em>spp.</p><p><em>Pseudomonas aeruginosa*</em></p><p><em>Pseudomonas fluorescens</em></p><p><em>Serratia marcescens*</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Anaerobic micro-organisms</u></p><p><em>Peptostreptococcus&nbsp;</em>spp.</p><p><em>Propionibacterium acnes</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>INHERENTLY RESISTANT ORGANISMS</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-positive micro-organisms</u></p><p><em>Actinomyces</em></p><p><em>Enteroccus faecium</em></p><p><em>Listeria monocytogenes</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-negative micro-organisms</u></p><p><em>Stenotrophomonas maltophilia</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Anaerobic micro-organisms</u></p><p><em>Excepted as listed above</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Other micro-organisms</u></p><p><em>Mycoplasma genitalium</em></p><p><em>Ureaplasma urealitycum</em></p></td></tr><tr><td style="vertical-align:top"><p>* Clinical efficacy has been demonstrated for susceptible isolates in approved clinical indications</p><p><sup>+&nbsp;</sup>Resistance rate &ge; 50% in one or more EU countries</p><p>($): Natural intermediate susceptibility in the absence of acquired mechanism of resistance</p><p>(1): Studies have been conducted in experimental animal infections due to inhalations of&nbsp;<em>Bacillus anthracis</em>&nbsp;spores; these studies reveal that antibiotics starting early after exposition avoid the occurrence of the disease if the treatment is made up to the decrease of the number of spores in the organism under the infective dose. The recommended use in human subjects is based primarily on&nbsp;<em>in-vitro</em>&nbsp;susceptibility and on animal experimental data together with limited human data. Two-month treatment duration in adults with oral ciprofloxacin given at the following dose, 500 mg bid, is considered as effective to prevent anthrax infection in humans. The treating physician should refer to national and/or international consensus documents regarding treatment of anthrax.</p><p>(2): Methicillin-resistant&nbsp;<em>S. aureus</em>&nbsp;very commonly express co-resistance to fluoroquinolones. The rate of resistance to methicillin is around 20 to 50% among all staphylococcal species and is usually higher in nosocomial isolates.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Following oral administration of single doses of 250 mg, 500 mg, and 750 mg of ciprofloxacin tablets, ciprofloxacin is absorbed rapidly and extensively, mainly from the small intestine, reaching maximum serum concentrations 1-2 hours later.</p><p>Single doses of 100-750 mg produced dose-dependent maximum serum concentrations (C<sub>max</sub>) between 0.56 and 3.7 mg/L. Serum concentrations increase proportionately with doses up to 1000 mg.</p><p>The absolute bioavailability is approximately 70-80%.</p><p>A 500 mg oral dose given every 12 hours has been shown to produce an area under the serum concentration-time curve (AUC) equivalent to that produced by an intravenous infusion of 400 mg ciprofloxacin given over 60 minutes every 12 hours.</p><p><u>Distribution</u></p><p>Protein binding of ciprofloxacin is low (20-30%). Ciprofloxacin is present in plasma largely in a non-ionised form and has a large steady state distribution volume of 2-3 L/kg body weight. Ciprofloxacin reaches high concentrations in a variety of tissues such as lung (epithelial fluid, alveolar macrophages, biopsy tissue), sinuses, inflamed lesions (cantharides blister fluid), and the urogenital tract (urine, prostate, endometrium) where total concentrations exceeding those of plasma concentrations are reached.</p><p><u>Biotransformation</u></p><p>Low concentrations of four metabolites have been reported, which were identified as: desethyleneciprofloxacin (M 1), sulphociprofloxacin (M 2), oxociprofloxacin (M 3) and formylciprofloxacin (M 4). The metabolites display&nbsp;<em>in-vitro</em>&nbsp;antimicrobial activity but to a lower degree than the parent compound.</p><p>Ciprofloxacin is known to be a moderate inhibitor of the CYP 450 1A2 iso-enzymes.</p><p><u>Elimination</u></p><p>Ciprofloxacin is largely excreted unchanged both renally and, to a smaller extent, faecally. The serum elimination half-life in subjects with normal renal function is approximately 4-7 hours.</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td colspan="3" style="vertical-align:top"><p>Excretion of ciprofloxacin (% of dose)</p></td></tr><tr><td rowspan="2" style="vertical-align:top">&nbsp;</td><td colspan="2" style="vertical-align:top"><p><strong>Oral Administration</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Urine</strong></p></td><td style="vertical-align:top"><p><strong>Faeces</strong></p></td></tr><tr><td style="vertical-align:top"><p>Ciprofloxacin</p></td><td style="vertical-align:top"><p>44.7</p></td><td style="vertical-align:top"><p>25.0</p></td></tr><tr><td style="vertical-align:top"><p>Metabolites (M<sub>1</sub>-M<sub>4</sub>)</p></td><td style="vertical-align:top"><p>11.3</p></td><td style="vertical-align:top"><p>7.5</p></td></tr></tbody></table><p>Renal clearance is between 180-300 mL/kg/h and the total body clearance is between 480-600 mL/kg/h. Ciprofloxacin undergoes both glomerular filtration and tubular secretion. Severely impaired renal function leads to increased half lives of ciprofloxacin of up to 12 h.</p><p>Non-renal clearance of ciprofloxacin is mainly due to active trans-intestinal secretion and metabolism. 1% of the dose is excreted via the biliary route. Ciprofloxacin is present in the bile in high concentrations.</p><p><u>Paediatric patients</u></p><p>The pharmacokinetic data in paediatric patients are limited.</p><p>In a study in children C<sub>max</sub>&nbsp;and AUC were not age-dependent (above one year of age). No notable increase in C<sub>max</sub>&nbsp;and AUC upon multiple dosing (10 mg/kg three times daily) was observed.</p><p>In 10 children with severe sepsis C<sub>max</sub>&nbsp;was 6.1 mg/L (range 4.6-8.3 mg/L) after a 1-hour intravenous infusion of 10 mg/kg in children aged less than 1 year compared to 7.2 mg/L (range 4.7-11.8 mg/L) for children between 1 and 5 years of age. The AUC values were 17.4 mg*h/L (range 11.8-32.0 mg*h/L) and 16.5 mg*h/L (range 11.0-23.8 mg*h/L) in the respective age groups.</p><p>These values are within the range reported for adults at therapeutic doses. Based on population pharmacokinetic analysis of paediatric patients with various infections, the predicted mean half-life in children is approx. 4-5 hours and the bioavailability of the oral suspension ranges from 50 to 80%.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazards for humans based on conventional studies of single dose toxicity, repeated dose toxicity, carcinogenic potential, or toxicity to reproduction.</p><p>Like a number of other quinolones, ciprofloxacin is phototoxic in animals at clinically relevant exposure levels. Data on photomutagenicity/ photocarcinogenicity show a weak photomutagenic or phototumorigenic effect of ciprofloxacin&nbsp;<em>in-vitro</em>&nbsp;and in animal experiments. This effect was comparable to that of other gyrase inhibitors.</p><p><u>Articular tolerability</u></p><p>As reported for other gyrase inhibitors, ciprofloxacin causes damage to the large weight-bearing joints in immature animals. The extent of the cartilage damage varies according to age, species and dose; the damage can be reduced by taking the weight off the joints. Studies with mature animals (rat, dog) revealed no evidence of cartilage lesions. In a study in young beagle dogs, ciprofloxacin caused severe articular changes at therapeutic doses after two weeks of treatment, which were still observed after 5 months.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Tablet core:</u></strong></p><p>Maize Starch,</p><p>Microcrystalline cellulose,</p><p>Sodium Lauryl Sulfate,</p><p>Magnesium Stearate,</p><p>Purified Talk,</p><p>Colloidal Anhydrous Silica,</p><p>Sodium Starch Glycolate</p><p>Crospovidone.</p><p><strong><u>Film-coat:</u></strong></p><p>Hypromellose,</p><p>Polyethyleneglycol,</p><p>Titanium Dioxide,</p><p>Simethicone emulsion</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Don&rsquo;t store above 30&deg;C. Store in a dry place. Protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>10 tablets in Aluminum - Aluminum blisters in a printed carton along with a leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Globalpharma Co. L.L.C., Dubai Investment Park, Jebel Ali, Dubai, U.A.E.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                22th April 2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>